Mario Cazzola

Q: What Schools Are Affiliated With Mario Cazzola

Mario Cazzola is affiliated with the following schools: University of Milan, MD Anderson Cancer Center, University of Pavia

Mario Cazzola's AcademicInfluence.com Rankings

Mario Cazzola

Physics

#2409

World Rank

#3568

Historical Rank

physics Degrees

Download Badge

Physics

Mario Cazzola's Degrees

PhD Physics University of Milan
Masters Physics University of Milan
Bachelors Physics University of Milan

Why Is Mario Cazzola Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Mario Cazzola's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (2016) (6707)
A gain-of-function mutation of JAK2 in myeloproliferative disorders. (2005) (3438)
Revised international prognostic scoring system for myelodysplastic syndromes. (2012) (2285)
Somatic mutations of calreticulin in myeloproliferative neoplasms. (2013) (1693)
Clinical and biological implications of driver mutations in myelodysplastic syndromes. (2013) (1493)
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. (2013) (1143)
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. (2011) (1090)
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. (2007) (980)
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. (2005) (827)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). (2010) (798)
Mutations and prognosis in primary myelofibrosis (2013) (659)
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013) (535)
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. (2014) (524)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study (2013) (506)
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. (2012) (472)
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. (2011) (466)
Outcomes for COPD pharmacological trials: from lung function to biomarkers (2008) (450)
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. (2004) (441)
Outcomes for COPD pharmacological trials: From lung function to biomarkers. (2008) (428)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. (2011) (413)
Pharmacology and Therapeutics of Bronchodilators (2012) (393)
Symptom variability in patients with severe COPD: a pan-European cross-sectional study (2010) (377)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer (2014) (358)
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. (2015) (346)
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. (2014) (345)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications (2010) (334)
Clinical significance of somatic mutation in unexplained blood cytopenia. (2017) (322)
The genetic basis of myelodysplasia and its clinical relevance. (2013) (316)
Myelodysplastic syndromes--coping with ineffective hematopoiesis. (2005) (312)
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. (2008) (302)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. (2017) (287)
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. (2006) (280)
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. (2014) (277)
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts (2008) (276)
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. (2013) (272)
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. (2005) (270)
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. (2008) (269)
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients (2014) (269)
Use of recombinant human erythropoietin outside the setting of uremia. (1997) (266)
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. (2013) (257)
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study (2007) (256)
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia (2010) (255)
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) (2011) (254)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. (2022) (249)
The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. (2010) (246)
Outdoor air pollution, climatic changes and allergic bronchial asthma (2002) (241)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. (2020) (238)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2019) (237)
Juvenile hemochromatosis locus maps to chromosome 1q. (1999) (236)
Translational pathophysiology: a novel molecular mechanism of human disease. (2000) (234)
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. (2012) (227)
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. (2014) (227)
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. (2013) (226)
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome (2011) (224)
Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. (1995) (218)
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. (2006) (218)
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells (2010) (216)
β2-agonist therapy in lung disease. (2013) (215)
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. (2011) (213)
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms (2015) (211)
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. (2016) (209)
p53 lesions in leukemic transformation. (2011) (207)
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis (2017) (205)
Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. (2003) (203)
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. (2015) (201)
A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. (2016) (201)
Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. (1998) (201)
Night-time symptoms: a forgotten dimension of COPD (2011) (200)
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. (2009) (200)
ACE2: The Major Cell Entry Receptor for SARS-CoV-2 (2020) (200)
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. (2012) (199)
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes (2015) (197)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. (2002) (193)
Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. (2004) (190)
Prevalence of Comorbidities in Patients with Chronic Obstructive Pulmonary Disease (2010) (189)
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders (2008) (189)
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. (2005) (187)
Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. (1996) (184)
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. (2016) (183)
The role of outdoor air pollution and climatic changes on the rising trends in respiratory allergy. (2001) (182)
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. (2014) (181)
Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. (1990) (177)
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. (2017) (177)
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron (2008) (177)
Mitochondrial ferritin: a new player in iron metabolism. (2002) (170)
Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells (2014) (169)
Gene expression profiling of CD34+ cells in patients with the 5q− syndrome (2007) (165)
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea (2013) (164)
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. (2011) (164)
Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai‐Dorfman disease) (1995) (162)
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. (2012) (162)
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. (2006) (159)
Natural history of juvenile haemochromatosis (2002) (159)
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. (2010) (157)
Integrated care pathways for airway diseases (AIRWAYS-ICPs) (2014) (155)
Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. (1995) (153)
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. (2007) (153)
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis (2015) (152)
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms (2015) (151)
Markers of disease severity in chronic obstructive pulmonary disease. (2006) (150)
β2‐adrenoceptor agonists: current and future direction (2011) (148)
The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. (2004) (148)
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. (2015) (147)
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms (2010) (146)
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. (2018) (146)
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial (2016) (144)
Hematologic passport for athletes competing in endurance sports: a feasibility study. (2003) (144)
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. (2009) (143)
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. (2014) (141)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (2019) (141)
Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? (2020) (140)
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. (2015) (139)
Novel long‐acting bronchodilators for COPD and asthma (2008) (135)
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. (2013) (135)
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. (2007) (134)
Once‐weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production (2003) (133)
NEW TOOLS FOR CLINICAL EVALUATION OF ERYTHRON FUNCTION IN MAN (1992) (130)
A moderate transfusion regimen may reduce iron loading in beta‐ thalassemia major without producing excessive expansion of erythropoiesis (1997) (128)
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome (2006) (128)
The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts (2008) (126)
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. (2007) (126)
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. (2014) (125)
Optimizing drug delivery in COPD: The role of inhaler devices. (2017) (124)
Effects of diesel exhaust particles on human lung epithelial cells: an in vitro study. (2007) (123)
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. (2013) (122)
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. (2017) (121)
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome (2005) (121)
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. (2016) (121)
Time-dependent changes in mortality and transformation risk in MDS. (2016) (120)
Relationship between transfusion regimen and suppression of erythropoiesis in β‐thalassaemia major (1995) (116)
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia (2018) (115)
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD (2003) (115)
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes (2014) (115)
TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. (2010) (114)
Clinical Severity and Thermodynamic Effects of Iron-responsive Element Mutations in Hereditary Hyperferritinemia-Cataract Syndrome* (1999) (113)
Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3) (2002) (113)
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. (2015) (113)
Ultra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary disease (2005) (110)
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. (2014) (110)
Hydroxyurea‐related toxicity in 3,411 patients with Ph'‐negative MPN (2012) (109)
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) (2015) (108)
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. (2016) (108)
Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis (2018) (107)
Are phosphodiesterase 4 inhibitors just more theophylline? (2006) (105)
Unbalanced X‐chromosome inactivation in haemopoietic cells from normal women (1998) (105)
Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes (2008) (105)
Italian real-life experience of omalizumab. (2010) (104)
Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. (2012) (104)
A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. (2007) (104)
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. (2005) (103)
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies (2012) (102)
The functional impact of adding salmeterol and tiotropium in patients with stable COPD. (2004) (102)
Asthma and comorbid medical illness (2010) (102)
Red blood cell precursor mass as an independent determinant of serum erythropoietin level. (1998) (101)
Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. (2015) (101)
Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. (2005) (101)
Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. (2016) (99)
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS (2020) (98)
Molecular mechanisms underlying airway smooth muscle contraction and proliferation: implications for asthma. (2008) (96)
Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemic cell lines. (1993) (96)
CD34-positive cells: biology and clinical relevance. (1995) (95)
Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee (2015) (95)
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. (2008) (95)
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. (2013) (95)
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. (2014) (94)
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders (2006) (94)
Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. (1999) (93)
Emerging inhaled bronchodilators: an update (2009) (93)
Clinical Pharmacokinetics of Salmeterol (2002) (93)
Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. (1987) (92)
Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. (2012) (92)
Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. (2011) (92)
Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. (2000) (91)
Saporin, a ribosome‐inactivating protein used to prepare immunotoxins, induces cell death via apoptosis (1996) (91)
Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R). (2004) (90)
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts (2013) (89)
Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. (1997) (88)
Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. (1997) (88)
Hereditary Hyperferritinemia-Cataract Syndrome: Relationship Between Phenotypes and Specific Mutations in the Iron-Responsive Element of Ferritin Light-Chain mRNA (1997) (86)
Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. (2014) (85)
Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. (1994) (85)
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. (2012) (84)
Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD. (2004) (82)
Emerging anti-inflammatory strategies for COPD (2012) (81)
Translational Study Searching for Synergy between Glycopyrronium and Indacaterol (2014) (81)
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. (2014) (81)
Clinical significance of genetic aberrations in secondary acute myeloid leukemia (2012) (81)
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis (2012) (80)
Additive effects of salmeterol and fluticasone or theophylline in COPD. (2000) (78)
The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). (2015) (78)
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis (2017) (77)
A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. (2000) (77)
Pharmacology and Therapeutics of Bronchodilators Revisited (2019) (74)
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone (2013) (72)
Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. (2010) (72)
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. (2014) (72)
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells (2016) (70)
Erythroid marrow function in anemic patients. (1987) (70)
The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera (2009) (70)
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms (2011) (69)
Leukemic transformation of polycythemia vera (2005) (69)
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group (2016) (69)
Natural history of idiopathic refractory sideroblastic anemia (1988) (69)
SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). (2020) (68)
Bronchodilators: current and future. (2014) (68)
Genetic and clinical heterogeneity of ferroportin disease (2005) (68)
Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. (2012) (68)
Transferrin saturation, plasma iron turnover, and transferrin uptake in normal humans. (1985) (67)
Classification and prognostic evaluation of myelodysplastic syndromes. (2011) (67)
A patient-oriented approach to treatment of myelodysplastic syndromes. (1998) (67)
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group (2012) (67)
Adding a LAMA to ICS/LABA Therapy: A Meta‐analysis of Triple Combination Therapy in COPD (2019) (66)
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. (2012) (66)
Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. (2006) (66)
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance (2017) (65)
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations (2007) (65)
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms (2011) (64)
Biologic and clinical significance of red cell ferritin. (1983) (64)
The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection (2015) (64)
Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. (2005) (64)
Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU) (2010) (64)
Adherence to COPD treatment: Myth and reality. (2017) (63)
The JAK2 V617F mutation in patients with cerebral venous thrombosis (2012) (63)
Inhaled β2-Adrenoceptor Agonists (2012) (62)
Ring sideroblasts and sideroblastic anemias (2011) (62)
One hundred years of chronic obstructive pulmonary disease (COPD). (2007) (62)
Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project (2014) (61)
The prevalence of asthma and COPD in Italy: a practice-based study. (2011) (61)
Soluble transferrin receptor as a potential determinant of iron loading in congenital anaemias due to ineffective erythropoiesis (1999) (60)
Oxidation pathway and exacerbations in COPD: the role of NAC (2016) (59)
Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. (2013) (58)
Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes (2008) (58)
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. (2017) (57)
Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias (1983) (57)
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. (2015) (57)
Combination of Formoterol and Tiotropium in the Treatment of COPD: Effects on Lung Function (2009) (56)
Gene expression and risk of leukemic transformation in myelodysplasia. (2017) (56)
THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision to the World Health Organization classi ﬁ cation of myeloid neoplasms and acute leukemia (2016) (56)
Comorbidities of asthma: current knowledge and future research needs (2013) (56)
Myelodysplastic Syndromes. (2020) (56)
Safety of inhaled corticosteroids: room for improvement. (2007) (56)
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. (2003) (55)
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation (2017) (55)
Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction. (2006) (54)
LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment (2017) (53)
Severe Asthma and Biological Therapy: When, Which, and for Whom (2019) (53)
A double‐blind, placebo‐controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen (1995) (53)
The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions (2018) (53)
A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. (1995) (53)
Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. (1993) (53)
Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM). (1988) (52)
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies (2011) (52)
Defining Phenotypes in COPD: An Aid to Personalized Healthcare (2014) (52)
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis (2016) (51)
Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? (2016) (51)
Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. (1994) (51)
A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea. (2009) (51)
Effects of Budesonide on P38 MAPK Activation, Apoptosis and IL-8 Secretion, Induced by TNF-α and Haemophilus Influenzae in Human Bronchial Epithelial Cells (2010) (51)
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome (2013) (51)
Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy. (2006) (51)
Brain natriuretic peptide: Much more than a biomarker. (2016) (50)
Pharmacological mechanisms leading to synergy in fixed‐dose dual bronchodilator therapy (2018) (50)
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia (2014) (50)
Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi (2011) (50)
Airflow obstruction: is it asthma or is it COPD? (2016) (50)
Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. (2015) (49)
Long-acting bronchodilators in COPD: where are we now and where are we going? (2014) (49)
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients (2015) (49)
Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. (1989) (49)
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. (2013) (49)
Circulating thrombopoietin in reactive conditions behaves like an acute phase reactant. (1999) (49)
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. (2017) (48)
Novel bronchodilators in asthma (2010) (48)
Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms (2014) (47)
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. (2017) (47)
Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. (2004) (47)
The use of bronchodilators in the treatment of airway obstruction in elderly patients. (2006) (47)
A review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challenges (2015) (47)
Biomarkers in COPD. (2010) (47)
ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? (2007) (47)
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes (2017) (47)
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. (2013) (47)
Respiratory allergic diseases induced by outdoor air pollution in urban areas. (2002) (47)
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. (2005) (47)
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 (2013) (47)
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera (2014) (46)
Mutational Landscape of the Transcriptome Offers Putative Targets for Immunotherapy of Myeloproliferative Neoplasms. (2019) (46)
Myelodysplastic syndromes: recent advances. (2001) (46)
Anti-TNF-α and Th1 cytokine-directed therapies for the treatment of asthma (2006) (46)
Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. (2003) (45)
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene (2015) (45)
Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells. (2009) (45)
SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines (2021) (45)
Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. (2001) (45)
The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera (2017) (44)
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome (2019) (44)
Markers of exacerbation severity in chronic obstructive pulmonary disease (2006) (44)
Prognostic classification and risk assessment in myelodysplastic syndromes. (2010) (44)
Estimation of Ferrokinetic Parameters by a Mathematical Model in Patients with Primary Acquired Sideroblastic Anaemia (1978) (44)
Germline RBBP6 mutations in familial myeloproliferative neoplasms. (2016) (43)
Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease (2014) (43)
Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. (2011) (43)
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. (2013) (43)
Disruption of SF 3 B 1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells (2015) (43)
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes (2008) (43)
Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. (1998) (42)
Microelectronic DNA chip for hereditary hyperferritinemia cataract syndrome, a model for large‐scale analysis of disorders of iron metabolism (2006) (42)
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. (2015) (42)
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine (2019) (42)
Biomarkers of lung damage associated with tobacco smoke in induced sputum. (2009) (42)
Sex differences in oncogenic mutational processes (2019) (41)
Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. (2010) (41)
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients withmyeloproliferative neoplasms. (2019) (41)
Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease (2015) (41)
Markers of exacerbation severity in chronic obstructive pulmonary disease. (2006) (41)
TSLP Inhibitors for Asthma: Current Status and Future Prospects (2020) (40)
A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. (1996) (40)
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms (2017) (40)
PDE inhibitors currently in early clinical trials for the treatment of asthma (2014) (39)
Cardiovascular disease in patients with COPD. (2015) (39)
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis (2002) (39)
TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. (2004) (39)
α1-Antitrypsin deficiency and chronic respiratory disorders (2020) (39)
The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. (2002) (39)
Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. (2017) (39)
Interaction between corticosteroids and muscarinic antagonists in human airways. (2016) (39)
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. (2011) (39)
Clinical significance of neutrophil CD177 mRNA expression in Ph‐negative chronic myeloproliferative disorders (2004) (39)
Somatic deletion of the normal β‐globin gene leading to thalassaemia intermedia in heterozygous β‐thalassaemic patients (2004) (39)
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases (2019) (38)
Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells (2015) (38)
Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. (2006) (38)
Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages (2017) (38)
Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. (2016) (38)
The Challenges of Precision Medicine in COPD (2017) (38)
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. (2017) (38)
How I treat essential thrombocythemia. (2016) (38)
Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD. (2015) (38)
LNK mutations in familial myeloproliferative neoplasms. (2016) (38)
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS (2020) (37)
Treatments for COPD. (2005) (37)
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies (2010) (37)
Molecular basis of myelodysplastic/myeloproliferative neoplasms (2009) (37)
The role of JAK2 mutations in RARS and other MDS. (2008) (37)
Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. (2004) (37)
Efficacy and safety profile of xanthines in COPD: a network meta-analysis (2018) (37)
Scanning mutations of the 5′UTR regulatory sequence of l‐ferritin by denaturing high‐performance liquid chromatography: identification of new mutations (2003) (37)
Identification of genomic aberrations associated with disease transformation by means of high‐resolution SNP array analysis in patients with myeloproliferative neoplasm (2011) (37)
An update on bronchodilators in Phase I and II clinical trials (2012) (37)
Characteristics of a ferritin‐binding protein present in human serum (1987) (37)
Refractory anemia with ring sideroblasts. (2013) (37)
Acute exacerbations of COPD: risk factors for failure and relapse (2017) (36)
JAK2 (V617F) mutation in healthy individuals (2007) (36)
Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. (2002) (36)
Myelodysplastic/myeloproliferative neoplasms. (2011) (36)
Leukemia risk models in primary myelofibrosis: an International Working Group study (2012) (36)
Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G‐CSF (2009) (36)
A systems medicine clinical platform for understanding and managing non- communicable diseases. (2014) (36)
Increase in leukocyte count over time predicts thrombosis in patients with low‐risk essential thrombocythemia (2009) (36)
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients (2017) (36)
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. (2016) (36)
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria (2017) (36)
Bronchial hyperresponsiveness and bacterial respiratory infections. (1991) (36)
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol (2013) (36)
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease (2016) (36)
Pharmacological characterization of adenosine receptors on isolated human bronchi. (2011) (36)
Role of ferritin and ferroportin genes in unexplained hyperferritinaemia. (2005) (36)
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (2017) (36)
A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS (2011) (35)
Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. (2019) (35)
Combined Cohesin-Runx1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes. (2020) (35)
The MABA approach: a new option to improve bronchodilator therapy (2013) (35)
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia (2006) (34)
Inflammation – A New Therapeutic Target in Pneumonia (2005) (34)
Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease (2013) (34)
Doxofylline is not just another theophylline! (2017) (34)
Internal distribution of excess iron and sources of serum ferritin in patients with thalassemia. (2009) (34)
LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review (2018) (34)
The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. (2010) (34)
RED CELL FERRITIN AS A DIAGNOSTIC TOOL (1986) (34)
Pets and cockroaches: two increasing causes of respiratory allergy in indoor environments. Characteristics of airways sensitization and prevention strategies. (2000) (34)
Diabetes mellitus among outpatients with COPD attending a university hospital (2014) (34)
Treating systemic effects of COPD. (2007) (34)
Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. (2011) (34)
Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety (2008) (34)
Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo (2020) (34)
Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. (2012) (33)
Natural history of idiopathic refractory sideroblastic anemia. (1988) (33)
Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study. (2018) (33)
A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. (2003) (33)
Chronic Obstructive Pulmonary Disease and Stroke (2018) (33)
Effect of acidic and basic isoferritins on in vitro growth of human granulocyte-monocyte progenitors. (1986) (33)
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease (2016) (33)
Immunotherapy with Alpare® in patients with respiratory allergy to Parietaria pollen: a two year double‐blind placebo‐controlled study (1995) (33)
A novel germline JAK2 mutation in familial myeloproliferative neoplasms (2014) (32)
The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis (2017) (32)
Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy (2018) (32)
Ferroportin gene silencing induces iron retention and enhances ferritin synthesis in human macrophages (2004) (32)
Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. (1995) (32)
Survivin Expression in Acute Leukemias and Myelodysplastic Syndromes (2004) (32)
Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases. (2004) (32)
Relationship between clone metrics and clinical outcome in clonal cytopenia. (2021) (32)
correspondence: Incidence of leukaemia in patients with primary myelofibrosis and RBC–transfusion‐dependence (2010) (32)
Respiratory infections and asthma (2005) (32)
Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukaemia autografted with Ph‐negative peripheral stem cells (1994) (31)
The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. (2007) (31)
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. (2015) (31)
The use of bronchodilators in stable chronic obstructive pulmonary disease. (1997) (31)
Immunomodulatory impact of a synbiotic in Th1 and Th2 models of infection (2010) (31)
Adequacy of iron supply for erythropoiesis: in vivo observations in humans. (1987) (31)
Comparative effectiveness of drugs for chronic obstructive pulmonary disease. (2012) (31)
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman (2004) (31)
Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study (2010) (31)
A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease. (1998) (31)
Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia (2015) (31)
Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma. (2000) (31)
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update (2016) (31)
Environment and development of respiratory allergy: I. Outdoors. (1994) (31)
Indacaterol for chronic obstructive pulmonary disease (COPD). (2010) (31)
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V 617 F mutation of Jak 2 (2005) (31)
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms (2017) (30)
Primary care of the patient with chronic obstructive pulmonary disease in Italy. (2009) (30)
Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma. (2006) (30)
Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease. (1998) (30)
Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view. (2008) (30)
Apoptosis: biological and clinical aspects. (1994) (29)
Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. (2006) (29)
A novel deletion of the l‐ferritin iron‐responsive element responsible for severe hereditary hyperferritinaemia–cataract syndrome (2002) (29)
Immunological Reactivity of Serum Ferritin in Patients with Malignancy (1985) (29)
The effective treatment of COPD: Anticholinergics and what else? (2006) (29)
Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist. (2000) (29)
Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives (2015) (29)
14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM) (2011) (29)
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia (2015) (29)
Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing. (2015) (29)
A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes. (2005) (29)
Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence (2013) (28)
Long acting β2 agonists and theophylline in stable chronic obstructive pulmonary disease (1999) (28)
Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies (2020) (28)
Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. (2013) (28)
Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. (2006) (28)
Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease (2020) (28)
Genetic disorders of iron overload and the novel "ferroportin disease". (2003) (28)
Theophylline in the inhibition of angiotensin-converting enzyme inhibitor-induced cough. (1993) (28)
Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. (2009) (28)
Killing of K562 cells with conjugates between human transferrin and a ribosome‐inactivating protein (SO‐6) (1988) (28)
COPD: the patient perspective (2016) (28)
The possible role of burden of therapy on the risk of myeloma extramedullary spread (2016) (28)
Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. (2001) (28)
Tremor and β(2)-adrenergic agents: is it a real clinical problem? (2012) (28)
Immune sensitization of equine bronchus: glutathione, IL-1β expression and tissue responsiveness (2005) (28)
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease (2014) (28)
Myelodysplastic/myeloproliferative disorders (2008) (27)
Controversy surrounding the Sputnik V vaccine (2021) (27)
Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways (2018) (27)
SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis (2020) (27)
IDH1 and IDH2 mutations in myeloid neoplasms – Novel paradigms and clinical implications (2010) (27)
Growth of human hematopoietic colonies from patients with myelodysplastic syndromes in response to recombinant human granulocyte-macrophage colony-stimulating factor. (1989) (27)
Preclinical Evaluation of an Inhibitor of Cytosolic Phospholipase A2α for the Treatment of Asthma (2011) (27)
Immunocytochemical detection of ferritin in human bone marrow and peripheral blood cells using monoclonal antibodies specific for the H and L subunit (1990) (27)
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi (2017) (27)
CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles (2017) (27)
Should long-acting beta 2-agonists be considered an alternative first choice option for the treatment of stable COPD? (1999) (26)
Triple combinations in chronic obstructive pulmonary disease – is three better than two? (2014) (26)
Tiotropium formulations and safety: a network meta-analysis (2017) (26)
Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma (2017) (26)
Effect of ketanserin, a new blocking agent of the 5‐HT2 receptor, on airway responsiveness in asthma (1990) (26)
Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. (2019) (26)
Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis (2008) (26)
Analysis of exhaled breath fingerprints and volatile organic compounds in COPD (2015) (26)
Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts (2016) (26)
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases (2017) (26)
Treatment of COPD: moving beyond the lungs. (2012) (26)
Pharmacological treatment and current controversies in COPD (2019) (26)
Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors (2013) (26)
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis (2009) (26)
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis (2020) (26)
Monoclonal gammopathy of undetermined significance: a new proposal of workup (2013) (26)
Muscarinic Receptor Antagonists. (2016) (25)
The role of indacaterol for chronic obstructive pulmonary disease (COPD). (2013) (25)
Transferrin receptor expression in the human placenta. (1990) (25)
Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold? (2014) (25)
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. (2019) (25)
A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation (1999) (25)
Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem‐cell transplantation: Report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo (2011) (25)
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project (2018) (25)
Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology. (2017) (24)
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. (2015) (24)
Novel Drivers and Modifiers of MPL-dependent Oncogenic Transformation Identified by Deep Mutational Scanning. (2019) (24)
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post‐ASH symposium (2012) (24)
Ultra-Long-Acting β2-Adrenoceptor Agonists (2012) (24)
Studies of Ineffective Erythropoiesis and Peripheral Haemolysis in Congenital Dyserythropoietic Anaemia Type II (1979) (24)
Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. (2004) (24)
Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study. (2010) (24)
Avoidance of allergens and air pollutants in respiratory allergy (2001) (24)
Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy (2011) (24)
Prospects for COPD treatment. (2020) (24)
Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin. (2000) (24)
Potential role of macrolides in the treatment of asthma. (2000) (24)
Delivering Antibacterials to the Lungs (2002) (24)
Metabolic syndrome and risk of pulmonary involvement. (2010) (24)
Ferrokinetic measurement of erythropoiesis. (1988) (24)
Clinical trial of the efficacy and safety of moguisteine in patients with cough associated with chronic respiratory diseases. (1993) (23)
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia (2006) (23)
Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease (2018) (23)
Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: A pilot study. (2010) (23)
Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis (2007) (23)
Use of a monoclonal antibody against human heart ferritin for evaluating acidic ferritin concentration in human serum (1985) (23)
Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review (2020) (23)
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. (2012) (23)
Differential HFE allele expression in hemochromatosis heterozygotes. (2001) (23)
Infection perturbs Bach2- and Bach1-dependent erythroid lineage ‘choice’ to cause anemia (2018) (23)
Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how (2018) (23)
Quality of Life and Economic Impact of Red Blood Cell (RBC) Transfusions on Patients with Myelodysplastic Syndromes (MDS). (2004) (23)
β-Adrenoceptor Modulation in Chronic Obstructive Pulmonary Disease: Present and Future Perspectives (2013) (23)
Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. (2019) (23)
General strategy for the management of bronchial asthma in pregnancy. (2003) (23)
The role of Pneumococcal vaccine. (2008) (23)
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (2018) (22)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Absent phenotypic expression of X-linked sideroblastic anemia in one of 2 brothers with a novel ALAS2 mutation. (2002) (22)
Independent prognostic impact of tumour‐infiltrating macrophages in early‐stage Hodgkin's lymphoma (2017) (22)
Effect of the selective 5-HT2 antagonist ketanserin on adenosine-induced bronchoconstriction in asthmatic subjects. (1992) (22)
Accelerated erythroid repopulation with no stem‐cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation (1993) (22)
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms (2017) (22)
Long-Acting β2 Agonists in the Management of Stable Chronic Obstructive Pulmonary Disease (2000) (22)
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes (2009) (22)
Use of 6-min and 12-min walking test for assessing the efficacy of formoterol in COPD. (2008) (22)
Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. (2009) (22)
Roflumilast in chronic obstructive pulmonary disease: evidence from large trials (2010) (22)
Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease (2007) (22)
Myelodysplastic syndromes: a multiparametric study of prognostic factors and a proposed scoring system. (1990) (22)
Quantitative evaluation of the mechanisms of the anaemia in heterozygous beta-thalassaemia. (2009) (22)
Comparative Effects of a Two-Week Treatment with Nebivolol and Nifedipine in Hypertensive Patients Suffering from COPD (2004) (22)
Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma. (2005) (21)
c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers. (1992) (21)
Juvenile genetic hemochromatosis is clinically and genetically distinct from the classical HLA-related disorder. (1998) (21)
Classification of anaemia on the basis of ferrokinetic parameters (1985) (21)
Ferritin in the red cells of normal subjects and patients with iron deficiency and iron overload (1983) (21)
Treatment with Erythropoietin and G-CSF Improves Survival in MDS Patients with Low Transfusion Need. (2006) (21)
Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists. (2013) (21)
Exclusion of ZIRTL as candidate gene of juvenile hemochromatosis and refinement of the critical interval on 1q21. (2000) (21)
Salmeterol/fluticasone propionate in a Single Inhaler Device versus theophylline+fluticasone propionate in patients with COPD. (2004) (21)
CD 34-POSITIVE CELLS : BIOLOGY AND CLINICAL RELEVANCE (21)
IL-17 in chronic obstructive pulmonary disease (2012) (21)
Review: Safety of long-acting β2 -agonists in the treatment of asthma (2007) (21)
Beta-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution. (2008) (21)
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD (2019) (21)
The effect of indacaterol during an acute exacerbation of COPD. (2013) (21)
Macrolide and occult infection in asthma (2004) (21)
Guidelines for the use of recombinant human erythropoietin. (1994) (20)
Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism. (2014) (20)
Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. (2015) (20)
Myelodysplastic Syndrome (MDS)-Specific Comorbidity Index for Predicting the Impact of Extra-Hematological Comorbidities on Survival of Patients with MDS (2008) (20)
Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone (2009) (20)
How and when to use erythropoietin (1998) (20)
The cardiovascular risk of tiotropium: is it real? (2010) (20)
Long-acting β2 agonists as potential option in the treatment of acute exacerbations of COPD (2003) (20)
Role of muscarinic antagonists in asthma therapy (2017) (20)
Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE st (2015) (20)
Effects of neuraminidase on equine isolated bronchi. (2008) (20)
Immunophenotypic, Cytogenetic and Functional Characterization of Circulating Endothelial Cells in Myelodysplastic Syndromes. (2006) (20)
Guidance on nebulization during the current COVID-19 pandemic (2020) (19)
Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time (1999) (19)
Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD. (2018) (19)
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. (2013) (19)
Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera (2012) (19)
MYD88 mutated and wild-type Waldenström’s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4 (2018) (19)
Hereditary hyperferritinaemia/ cataract syndrome. (2002) (19)
Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease (1999) (19)
Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients. (2007) (19)
An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression (1991) (19)
Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors. (1991) (19)
Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. (2016) (19)
Azithromycin and lower respiratory tract infections (2005) (19)
Cerebrospinal fluid ferritin in human disease. (1986) (19)
The future of bronchodilation: looking for new classes of bronchodilators (2019) (19)
Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi (2017) (19)
The role of combination therapy with corticosteroids and long-acting β2-agonists in the prevention of exacerbations in COPD (2006) (19)
Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. (1995) (19)
Ruxolitinib treatment and risk of B‐cell lymphomas in myeloproliferative neoplasms (2019) (19)
Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease. (1997) (18)
Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study, (2011) (18)
Long-acting bronchodilators improve health related quality of life in patients with COPD. (2013) (18)
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes (2019) (18)
Long-term Results From a Phase II Open-label Study of Ruxolitinib in Patients With Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea (2014) (18)
Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome (2022) (18)
Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. (2019) (18)
Comparative study of dirithromycin and azithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis. (1999) (18)
Impact of doxofylline in COPD: A pairwise meta-analysis. (2018) (18)
Myelodysplastic syndrome with monosomy 7 in adulthood: a distinct preleukaemic disorder. (1983) (18)
Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera (2018) (18)
Both cycling and noncycling primitive progenitors continue to be mobilized into the circulation during the leukapheresis of patients pretreated with chemotherapy and G‐CSF (1997) (18)
Recombinant human erythropoietin is effective in correcting erythropoietin‐deficient anaemia after allogeneic bone marrow transplantation (1992) (18)
Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers (2019) (18)
Flow Cytometry Evaluation of Erythroid Dysplasia in Patients with Myelodysplastic Syndrome. (2004) (18)
Emerging drugs for chronic obstructive pulmonary disease (2012) (17)
Advances with glucocorticoids in the treatment of asthma: state of the art (2020) (17)
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms (2014) (17)
Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study (2011) (17)
Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease (1999) (17)
Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2). (2018) (17)
Ketanserin, a new blocking agent of serotonin S2-receptors. Respiratory functional effects in chronic obstruction of the airways. (1987) (17)
Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. (2018) (17)
Interferons as biologic modulators of hematopoietic cell proliferation and differentiation. (1988) (17)
Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing‐Neel syndrome (2015) (16)
Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. (1983) (16)
Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis. (2006) (16)
Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach? (2018) (16)
The effect of pet ownership on the risk of allergic sensitisation and bronchial asthma. (2005) (16)
Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphase‐FISH (2013) (16)
Umeclidinium for the treatment of chronic obstructive pulmonary disease (2014) (16)
Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta2-agonists. (2007) (16)
Myelodysplastic syndromes: biologic and clinical aspects. (1986) (16)
Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition. (2013) (16)
Comparison of the Bronchodilating Effect of Salmeterol and Zafirlukast in Combination with That of Their Use as Single Treatments in Asthma and Chronic Obstructive Pulmonary Disease (2001) (16)
Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. (2009) (16)
An improved method for liquid scintillation counting of 59Fe in ferrokinetic studies. (1974) (16)
Application of Number Needed to Treat (NNT) as a Measure of Treatment Effect in Respiratory Medicine (2006) (16)
Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia (2014) (16)
Problems and prospectives in the antibiotic treatment of lower respiratory tract infections. (1994) (16)
Inhaled corticosteroids for chronic obstructive pulmonary disease (2013) (16)
Fixed-Dose Combination Inhalers. (2016) (16)
Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia. (2022) (16)
Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia (2009) (16)
Bifunctional Drugs for the Treatment of Respiratory Diseases. (2017) (16)
Disease anticipation in familial myeloproliferative neoplasms. (2008) (16)
Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. (1999) (16)
Neurological Complications Involving the Central Nervous System After Allogeneic Hematopoietic Stem Cell Transplantation During a Period of Evolution in Transplant Modalities: A Cohort Analysis (2017) (16)
Pilot trial of combined administration of erythropoietin and granulocyte colony-stimulating factor to children undergoing allogeneic bone marrow transplantation. (1994) (16)
Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. (2002) (16)
Interrelationship between pharmacokinetics and pharmacodynamics in choosing the appropriate antibiotic and the dosage regimen for treating acute exacerbations of chronic bronchitis. (1998) (15)
Preexisting cardiorespiratory comorbidity does not preclude the success of multidisciplinary rehabilitation in post-COVID-19 patients (2021) (15)
New insights in allergen avoidance measures for mite and pet sensitized patients. A critical appraisal. (2005) (15)
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network (2016) (15)
Iron metabolism in thalassemia. (1988) (15)
Long‐acting muscarinic antagonists and small airways in asthma: Which link? (2021) (15)
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease (2015) (15)
Denaturing HPLC analysis of DNA deletions and insertions (2003) (15)
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. (2018) (15)
How does race/ethnicity influence pharmacological response to asthma therapies? (2018) (15)
Further concerns about the medical risks of blood doping. (2002) (15)
Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction. (2002) (15)
Bronchodilator therapy for chronic cough. (2017) (14)
Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation (2014) (14)
Non-Pulmonary Effects Induced by the Addition of Formoterol to Budesonide Therapy in Patients with Mild or Moderate Persistent Asthma (2000) (14)
A Prognostic Model for Predicting the Impact of Comorbidities on Survival of Patients with Myelodysplastic Syndromes. (2007) (14)
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? (2018) (14)
Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD. (1999) (14)
Novel glucocorticoid receptor agonists in the treatment of asthma (2015) (14)
Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs. (2005) (14)
Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent (2020) (14)
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab (2018) (14)
Influence of ethnicity on response to asthma drugs (2015) (14)
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders. (2006) (14)
Novel genes, proteins, and inherited disorders of iron overload: iron metabolism is less boring than thought. (2002) (14)
The latest on the role of LAMAs in asthma. (2020) (14)
Effects of recombinant human H‐subunit and L‐subunit ferritins on in vitro growth of human granulocyte—monocyte progenitors (1988) (14)
P-113 The efficacy and tolerabilityof ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overload (2005) (14)
A potential role of triple therapy for asthma patients (2019) (14)
Dual bronchodilatory and pulmonary anti‐inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors (2010) (13)
Induced sputum as a tool for early detection of airway inflammation in connective diseases-related lung involvement. (2007) (13)
Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease (2015) (13)
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2 (2013) (13)
Red cell aplasia in myelofibrosis with myeloid metaplasia. A distinct functional and clinical entity (1983) (13)
Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections (2003) (13)
Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms (2011) (13)
Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. (2005) (13)
N-acetylcysteine in COPD may be beneficial, but for whom? (2014) (13)
POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes. (2018) (13)
The effect of doxofylline in asthma and COPD. (2020) (13)
Respiratory responses to pirenzepine in healthy subjects. (1987) (13)
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients (2019) (13)
Cell kinetics of CD34‐positive hematopoietic cells following chemotherapy plus colony‐stimulating factors in advanced breast cancer (1995) (13)
N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. (2018) (13)
Mutant calreticulin: when a chaperone becomes intrusive. (2016) (13)
Molecular basis of thrombocytosis (2008) (13)
Use of Thiols in the Treatment of COVID-19: Current Evidence (2021) (13)
The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy (2021) (13)
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project (2018) (13)
Antibodies for denatured human H‐ferritin stain only reticuloendothelial cells within the bone marrow (1992) (13)
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. (2019) (13)
Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach (2022) (12)
Impact of rokitamycin, a new 16-membered macrolide, on serum theophylline. (1991) (12)
Potential genetic influences on the response to asthma treatment. (2004) (12)
Erythropoietin therapy: need for rationality and active surveillance. (2003) (12)
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2020) (12)
Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells (2018) (12)
Pulmonary penetration of ceftazidime. (1995) (12)
[Hyperferritinemia-cataract syndrome associated to the HFE gene mutation. Two new Spanish families and a new mutation (A37T: "Zaragoza")]. (2006) (12)
Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients (2019) (12)
Recombinant gamma-interferon induces in vitro monocytic differentiation of blast cells from patients with acute nonlymphocytic leukemia and myelodysplastic syndromes. (1988) (12)
Chronic myelogenous leukemia following radiotherapy and chemotherapy for non-Hodgkin lymphoma. (1990) (12)
Novel approaches to the treatment of pneumonia. (2003) (12)
Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia. (2009) (12)
Germline RBBP6 Mutations In Myeloproliferative Neoplasms (2013) (12)
Pulmonary penetration of dirithromycin in patients suffering from acute exacerbation of chronic bronchitis. (1994) (12)
Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. (2019) (12)
Inhaled medication: which device for which patient? (2015) (12)
Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease (2019) (12)
Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: forme‐fruste of Churg‐Strauss syndrome? (2009) (12)
Prognostic parameters in myelodysplastic syndromes: A multiple regression analysis (1988) (12)
Alternative and/or integrative therapies for pneumonia under development (2004) (12)
Participation of GABAergic mechanisms in the hypotensive and bradycardic effects of clonidine: Experimental study in conscious normotensive and hypertensive rats (1987) (11)
Polycythaemia following splenectomy in myelofibrosis with myeloid metaplasia. A reorganization of erythropoiesis. (2009) (11)
Recent Advances in Myelodysplastic Syndromes (1998) (11)
Clonal monocytosis of clinical significance. (2019) (11)
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. (2018) (11)
RNAmut: robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing (2020) (11)
Parenteral antibiotic therapy in the treatment of lower respiratory tract infections. Strategies to minimize the development of antibiotic resistance. (2000) (11)
The protective role of epithelium-derived nitric oxide in isolated bovine trachea. (2002) (11)
Long-Acting β2-Agonists in the Treatment of Acute Exacerbations of COPD (2002) (11)
LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients (2016) (11)
Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation (2019) (11)
Advances in the research and development of chemotherapeutic agents for respiratory tract bacterial infections. (2001) (11)
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils (2016) (11)
Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease. (2006) (11)
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma (2013) (11)
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. (2013) (11)
Treatable Mechanisms in Asthma (2021) (11)
The safety of dual bronchodilation on cardiovascular serious adverse events in COPD (2018) (11)
An approach by means of mathematical models to the analysis of ferrokinetic data obtained by liquid scintillation counting of 59Fe. (1976) (11)
Treatment options for moderate-to-very severe chronic obstructive pulmonary disease (2016) (10)
Bronchodilators in subjects with asthma-related comorbidities. (2019) (10)
Diabetes insipidus in the preleukaemic phase of acute non-lymphocytic leukaemia. A monosomy 7-associated condition? (2009) (10)
JAK inhibitor in CALR-mutant myelofibrosis. (2014) (10)
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. (2012) (10)
A simple method for simultaneous liquid scintillation counting of 59Fe and 51Cr in blood (1976) (10)
Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review (2020) (10)
Blast phase of essential thrombocythemia: A single center study (2009) (10)
A review of the pharmacokinetics of M3 muscarinic receptor antagonists used for the treatment of asthma (2020) (10)
Hypereosinophilic syndrome and cyclic oscillations in blood cell counts. A clonal disorder of hematopoiesis originating in a pluripotent stem cell. (2004) (10)
Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD. (2016) (10)
Ultra-LABAs for the treatment of asthma. (2019) (10)
Evaluation of lung tissue and hilar lymph node concentrations of azithromycin. (1994) (10)
Iron kinetics and erythropoiesis in Fanconi's anaemia. (2009) (10)
Somatic Mutation of SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts (2011) (10)
Erythrophagocytosis increases the expression of erythroid potentiating activity mRNA in human monocyte-macrophages. (1993) (10)
Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol (2015) (10)
New treatments for COPD in the elderly. (2014) (10)
Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis (2019) (10)
Evaluation of erythroid marrow function in anemic patients. (1987) (10)
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease (2015) (10)
X-linked Wiskott-Aldrich syndrome in a girl. (1998) (10)
Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting (2018) (10)
Establishment and characterization of a B‐cell line derived from a patient with a myelodysplastic syndrome which expresses myelomonocytic and lymphoid markers (1991) (10)
Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome. (2000) (10)
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation (2010) (10)
Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. (2018) (9)
Erythroid Activity, Transfusion Iron Overload, and Hepcidin Levels in Patients with Myelodysplastic Syndrome (2008) (9)
Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review (2020) (9)
[The plasma 59Fe clearance curve in man. An evaluation of methods of measurement and analysis]. (1980) (9)
A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT). (2009) (9)
Pharmacokinetics and Pharmacodynamics of Newer Oral Cephalosporins (1998) (9)
Germline DDX41 mutations define a unique subtype of myeloid neoplasms. (2022) (9)
To add, or not to add an inhaled corticosteroid in moderate COPD: that is the question. (2008) (9)
Expression of adhesion molecules and functional stimulation in human neutrophils: modulation by GM‐CSF and role of the Bcr gene (1997) (9)
The clinical use of regenerative therapy in COPD (2014) (9)
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia (2005) (9)
Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells. (1994) (9)
Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors (2013) (9)
Kaposi's Sarcoma Complicating Immunosuppressive Therapy for Angioimmunoblastic Lymphadenopathy with Dysproteinemia (1982) (9)
Is ICS-LAMA an alternative option to treat patients with COPD? (2018) (9)
Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae. (2005) (9)
TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee (2014) (9)
An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS) (2015) (9)
Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations: a European Multicenter Study (2009) (9)
Marked down‐regulation of nucleophosmin‐1 is associated with advanced del(5q) myelodysplastic syndrome (2011) (9)
Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD. (2002) (9)
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes (2020) (9)
New anti-inflammatory approaches in COPD (2004) (9)
Transferrin saturation, plasma iron turnover, and transferrin uptake in normal humans (1985) (9)
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms (2020) (9)
One hundred years of respiratory medicine chronic obstructive pulmonary disease (COPD)—Republished article (2008) (9)
Cold haemagglutinin disease with severe anaemia, reticulocytopenia and erythroid bone marrow. (2009) (9)
A five-day course of dirithromycin in the treatment of acute exacerbation of severe chronic obstructive pulmonary disease. (1997) (9)
Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD. (2008) (8)
Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses (2019) (8)
Effects of in vitro 5-HT1 receptor activation in guinea pig trachea. (1996) (8)
TNF- (cid:11) inhibitors in asthma and COPD: we must not throw the baby out with the bath water (2016) (8)
An update on the pharmacotherapeutic management of lower respiratory tract infections (2017) (8)
Mitochondrial Ferritin Expression and Clonality of Hematopoiesis in Patients with Refractory Anemia with Ringed Sideroblasts. (2005) (8)
New Avenues for Phosphodiesterase Inhibitors in Asthma (2021) (8)
Acute respiratory and cardiovascular effects of inhaled ketanserin in chronic obstructive pulmonary disease. A comparative study with intravenously administered ketanserin. (1990) (8)
Response‐adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression‐free survival in transplanted patients with multiple myeloma (2012) (8)
Iron balance in thalassemia. (1989) (8)
An Acute Bronchodilator Test with Tiotropium or Salmeterol Does Not Allow a Subdivision of Patients according to Responses (2005) (8)
Varenicline for long term smoking cessation in patients with COPD. (2018) (8)
A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. (2009) (8)
Sex differences in COPD management (2021) (8)
Erratum: The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes (The Journal of clinical investigation (2017) 127 6 (2206-2221) PII: 96202) (2017) (8)
A case scenario study on adherence to COPD GOLD recommendations by general practitioners in a rural area of southern Italy: The "progetto PADRE". (2020) (8)
Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation (2021) (8)
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. (2014) (8)
Therapies in development for community-acquired pneumonia (2002) (8)
An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD (2018) (8)
Allelic imbalance in CALR somatic mutagenesis (2015) (8)
COLD-PCR and innovative microarray substrates for detecting and genotyping MPL exon 10 W515 substitutions. (2012) (8)
Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings (2020) (8)
Measurement of Ferritin-Bearing Lymphocytes in Man. Preliminary Studies on the Use of Monoclonal Antibodies Specific for the L and H Subunits of Ferritin (1987) (8)
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma (2018) (8)
Bacterial isolates and cigarette smoking in patients with chronic bronchitis: results from an Italian multicenter survey. (1990) (8)
Mechanisms and characteristics of airway sensitization to indoor allergens. (2001) (8)
Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma (2016) (7)
842-3 Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anemia in patients with chronic heart failure (2004) (7)
X-linked chronic granulomatous disease in an adult woman. Evidence for a cell selection favoring neutrophils expressing the mutant allele. (1985) (7)
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug. (2004) (7)
It's about time--directing our attention toward modifying the course of COPD. (2008) (7)
Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome (2009) (7)
Tumor necrosis factor alpha modulates the messenger RNA expression of hematopoietic growth factor genes in fresh blast cells from patients with acute myeloblastic leukemia. (1991) (7)
Effects of some cephalosporins and teicoplanin on platelet aggregation. (1993) (7)
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma (2012) (7)
Refractory cytopenias: Clinical course according to bone marrow cytology and cellularity (1987) (7)
Autografting with Ph-negative progenitors in patients at diagnosis of chronic myeloid leukemia induces a prolonged prevalence of Ph-negative hemopoiesis. (2000) (7)
Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease (2018) (7)
Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage. (2014) (7)
Comprehensive Analysis of Aberrant RNA Splicing in Myelodysplastic Syndromes (2014) (7)
Novelties in the field of antimicrobial compounds for the treatment of lower respiratory tract infections. (2003) (7)
"In vitro" megakaryocytopoiesis in patients with HIV-related thrombocytopenic purpura. (1988) (7)
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. (2021) (7)
Validation of cytogenetic-based risk stratification in primary myelofibrosis. (2010) (7)
Benefits and risks of JAK inhibition. (2018) (7)
Indacaterol for the treatment of chronic obstructive pulmonary disease (2015) (7)
Novel oral cephalosporins (2000) (7)
Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. (2019) (7)
Cutaneous and serological responses to cat allergen in adults exposed or not to cats. (2005) (7)
The Effect of Transfusion Dependency and Secondary Iron Overload on Survival of Patients with Myelodysplastic Syndrome. (2005) (7)
Aclidinium bromide for the treatment of chronic obstructive pulmonary disease (2013) (7)
Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD. (2011) (7)
The dysmetabolic iron overload syndrome is clinically and genetically distinct from HFE-related genetic hemochromatosis. (1999) (7)
The role of triple therapy in the management of COPD (2020) (7)
Emerging muscarinic receptor antagonists for the treatment of asthma (2020) (7)
The use of 59Fe for estimating red cell production and destruction: a comparative evaluation of two methods for the analysis of experimental data. (1979) (7)
Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease (2020) (7)
Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond (2014) (7)
Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler. (2003) (7)
Onset of Action of Formoterol versus Salmeterol via Dry Powder Inhalers in Moderate Chronic Obstructive Pulmonary Disease (2012) (7)
Erratum: Genetic and clinical heterogeneity of ferroportin disease (British Journal of Haematology (2005) 131, (663-670)) (2006) (7)
An M1-selective muscarinic receptor antagonist telenzepine improves lung function in patients with chronic obstructive bronchitis. (1990) (6)
Role of 5-hydroxytryptamine in mediating adenosine-induced airway contraction. (1995) (6)
Identification of Gene Expression Based Prognostic Markers in the Hematopoietic Stem Cells of Patients with Myelodysplastic Syndromes (2012) (6)
Clinical pharmacokinetics of theophylline during co-treatment with ticarcillin plus clavulanic acid in patients suffering from acute exacerbation of chronic bronchitis. (1993) (6)
COPD diagnosis by a gas sensor array (2010) (6)
Combining Dual Bronchodilation and β-Blockade in Patients With an Overlap Between COPD and Cardiovascular Diseases. (2018) (6)
Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. (2015) (6)
Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia. (1987) (6)
Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: a translational bench-to-bedside study. (2021) (6)
O-001 Clinical and biological implications of gene mutations in MDS (2013) (6)
Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life (2015) (6)
Spleen iron content is low in thalassemia. (1984) (6)
Evidence of muscarinic receptor subtypes in airway smooth muscle of normal volunteers and of chronic obstructive pulmonary disease patients. (1989) (6)
Critical evaluation of guidelines for the treatment of lower respiratory tract bacterial infections. (2001) (6)
Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease (2015) (6)
Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease. (2000) (6)
Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy in patients with solid tumors. (1996) (6)
Influence of sulbactam plus ampicillin on theophylline clearance. (1991) (6)
A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM) (2014) (6)
In vitro and in vivo effects of recombinant interferon gamma on the growth of hematopoietic progenitor cells from patients with myelodysplastic syndrome. (1989) (6)
In vitro growth of bone marrow-derived multipotent and lineage-restricted hematopoietic progenitor cells in myelodysplastic syndromes. (1989) (6)
From large clinical trials to management of COPD in the real world (2009) (6)
Cardiovascular Disease in Chronic Respiratory Disorders and Beyond. (2019) (6)
Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. (2017) (6)
Energy expenditure and impact of bronchodilators in COPD patients. (2010) (6)
Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib. (2004) (6)
The relevance of transfusion‐dependency in the prognostic assessment of patients with myeloid neoplasms (2011) (6)
Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies (2015) (6)
Pharmacogenetic and pharmacogenomic considerations of asthma treatment (2017) (6)
Morphological and cytochemical studies of circulating Hodgkin's and Reed-Sternberg cells. (1980) (6)
SMART for the treatment of asthma: A network meta-analysis of real-world evidence. (2021) (6)
Aclidinium/formoterol fixed-dose combination for the treatment of chronic obstructive pulmonary disease. (2015) (6)
Intrapulmonary penetration of antimicrobials and implications in the treatment of lower respiratory tract infections (2004) (6)
Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic scoring System (IPSS-R) (2014) (6)
The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease (2010) (6)
Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group (2019) (6)
Prevalence and Clinical Significance of the MYD88 (L265P) Somatic Mutation in Patients with Waldenström Macroglobulinemia, IgM-Monoclonal Gammopathy of Undetermined Significance or Other Mature B-Cell Neoplasms. (2012) (6)
Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis (2021) (6)
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide (2020) (6)
Long-acting beta(2) agonists as potential option in the treatment of acute exacerbations of COPD. (2003) (5)
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD (2018) (5)
New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology (2018) (5)
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis (2015) (5)
PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms (2022) (5)
Interrelationship Between the Pharmacokinetics and Pharmacodynamics of Cefaclor Advanced Formulation in Patients with Acute Exacerbations of Chronic Bronchitis (2000) (5)
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia (2007) (5)
Clinical evaluation of erythrocyte zinc-protoporphyrin as a parameter of iron status in man. (1984) (5)
Bronchodilating effect of oxitropium bromide in heart disease patients with exacerbations of COPD: double-blind, randomized, controlled study. (2002) (5)
Clinical synergism of LABA/LAMA combinations in COPD patients (2017) (5)
Ineffective erythropoiesis and its treatment. (2021) (5)
Cefaclor in the treatment of infective exacerbations of chronic bronchitis in cigarette smokers. (1991) (5)
Pulmonary Disposition of Lomefloxacin in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. A Multiple-Dose Study (2001) (5)
Prulifloxacin in the treatment of acute exacerbations of COPD in cigarette smokers (2008) (5)
Effect of telenzepine, an M1-selective muscarinic receptor antagonist, in patients with nocturnal asthma. (1994) (5)
Cardiovascular effects of thallium sulfate after intracerebroventricular administration in normotensive rats (1987) (5)
Autonomic nervous system dysfunction in the course of active pulmonary tuberculosis. (2007) (5)
Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy (2020) (5)
The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians (2020) (5)
Triple Therapy Is Also Effective in Real-World When Used in Chronic Obstructive Pulmonary Disease Patients Who Are Frequent Exacerbators (2021) (5)
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms (2014) (5)
Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms (2017) (5)
Olodaterol + tiotropium bromide for the treatment of COPD (2016) (5)
Pharmacological management of adult patients with acute respiratory distress syndrome (2020) (5)
Cardiovascular and respiratory effects of spermidine and spermine: an experimental study. (1984) (5)
Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms (2013) (5)
Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms (2020) (5)
Arformoterol tartrate in the treatment of COPD (2010) (5)
Evidence for the existence of two populations of erythroid cells in a case of congenital dyserythropoietic anaemia type II. (1982) (5)
Protein tyrosin kinase and KCa++ cannel: two faces of the same coin in LABA/LAMA synergy (2017) (5)
Pathophysiological classification of acquired bone marrow failure based on quantitative assessment of erythroid function (1987) (5)
Benralizumab for the treatment of asthma. (2017) (5)
Combination treatment in asthma: Reviewing old and new options. (2015) (5)
Pulmonary pharmacokinetics of dirithromycin allow a 5-day treatment of acute bacterial exacerbation of chronic bronchitis (1995) (5)
Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile (2020) (4)
An in vitro study of the possible interaction between human platelets and cephalosporins. (1991) (4)
New perspectives on the role of muscarinic antagonists in asthma therapy (2020) (4)
Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. (1990) (4)
Prognostic relevance of anemia in myelodysplastic syndromes (2008) (4)
Assessing the viability of long-acting β2-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective (2017) (4)
Is it time to look beyond bronchodilators and corticosteroids in treating COPD? (2021) (4)
P-113 Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM (2013) (4)
Identification of Novel Somatic Mutations in SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts and Other Common Cancers (2011) (4)
Telithromycin in lower respiratory tract infections. (2006) (4)
Novel Approaches to the Treatment of Bacterial Lower Respiratory Tract Infections: Introduction (2005) (4)
Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD) (2020) (4)
An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease (2021) (4)
Relationship Between Granulocyte JAK2 (V617F) Mutant Allele Burden and Risk of Progression to Myelofibrosis in Polycythemia Vera: a Prospective Study of 338 Patients. (2009) (4)
Disputes over the production and dissemination of misinformation in the time of COVID-19 (2021) (4)
An Obvious Paradigm: Choosing Bronchodilators and Inhaled Corticosteroids for Their Pharmacologic Characteristics. (2021) (4)
Asthma control: evidence-based monitoring and the prevention of exacerbations (2008) (4)
Treatment of asthma during pregnancy: more solid evidence needed (2008) (4)
Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications (2017) (4)
Dual bronchodilation and exacerbations of COPD. (2016) (4)
The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis (2013) (4)
Juvenile chronic myelogenous leukemia: in vitro characterization before and after allogeneic bone marrow transplantation. (1995) (4)
Response to recombinant human erythropoietin (rHuEpo) in patients with cancer-related anaemia (1993) (4)
Research on heterocyclic compounds. XVIII. Imidazo[2,1-b]-1,3,4-thiadiazole derivatives. (1985) (4)
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? (2016) (4)
Role of M1 muscarinic receptor subtypes in mediating airway smooth muscle contraction. (1993) (4)
Step-up and step-down approaches in the treatment of asthma (2021) (4)
SF3B1 Mutation Is an Independent Predictor of Parenchymal Iron Overload in Myelodysplastic Syndromes (2015) (4)
Disease anticipation in familial myeloproliferative neoplasms. Authors' reply (2008) (4)
A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. (2019) (4)
The end of a long search: at last thrombopoietin. (1994) (4)
Molecular basis of congenital dyserythropoietic anemia type II and genotype-phenotype relationship (2010) (4)
Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents (2018) (4)
Classes of drugs that target the cellular components of inflammation under clinical development for COPD (2021) (4)
Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm (2015) (4)
Double or Triple Therapy in Chronic Obstructive Pulmonary Disease (2018) (4)
Association of β2-adrenergic agonists and tiotropium:is the combination justified? (2005) (4)
P-104 Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDS With del(5q) in MDS-003 and MDS-004: A retrospective analysis (2013) (4)
Olodaterol for the treatment of asthma (2016) (4)
Cardiovascular effects of intracerebral injections of glutamate and kainate in rats. (1988) (4)
Current opinion: Pharmacological approaches in asthma and COPD (2009) (4)
Antibiotics and the Lung (2004) (4)
Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis (2013) (4)
Can FeNO be a biomarker in the post-COVID-19 patients monitoring? (2022) (4)
Have guidelines for the management of community-acquired pneumonia influenced outcomes? (2003) (3)
Different Mutant Splicing Factors Cause Distinct Missplicing Events and Give Rise to Different Clinical Phenotypes in Myelodysplastic Syndromes (2015) (3)
Indacaterol/Glycopyrronium Combination for COPD (2017) (3)
Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma (2020) (3)
Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004) (2010) (3)
Erythropoiesis in hairy cell leukaemia: a true erythroid failure. (2009) (3)
Competing models for the analysis of red cell survival obtained with 51Cr labelling technique. (2009) (3)
Interaction between tiotropium bromide and olodaterol in human bronchial smooth muscle (2017) (3)
Bronchodilators for Airway Disease (2020) (3)
Abstract 5552: Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408 (2014) (3)
Impaired virus‐specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib (2020) (3)
Introduction to a review series on iron metabolism and its disorders. (2019) (3)
Acute e ¡ ects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD (2002) (3)
Secreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms. (2022) (3)
Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS) (2016) (3)
Congenital Erythropoietin-Dependent Erythrocytosis Responsive to Theophylline Treatment (1998) (3)
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data (2020) (3)
The effects of cefonicid on the pharmacokinetics of a once-a-day theophylline formulation. (1989) (3)
Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study) (2014) (3)
Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs (2022) (3)
Acute promyelocytic leukemia complicating chemo-radiotherapy for multiple myeloma. (1996) (3)
A competitive European Hematology Journal (2005) (3)
Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma (2012) (3)
Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to the WHO Criteria. A Basis for Clinical Decision-Making. (2004) (3)
Corticosteroids in COPD (2003) (3)
Serum Digoxin Levels After Concomitant Ticarcillin and Clavulanic Acid Administration (1994) (3)
Diagnostic approach to the myelodysplastic syndromes. (1992) (3)
Response to “The WHO classification of haematolymphoid tumours” (Editorial) (2022) (3)
Dual bronchodilation for the treatment of COPD: From bench to bedside (2022) (3)
Long-acting β2 agonists in asthma and allergic rhinitis (2008) (3)
A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results (2013) (3)
The origin of serum ferritin in acquired transfusional iron overload in adults. Studies with concanavalin A-sepharose absorption. (1982) (3)
Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review (2020) (3)
Cough and asthma: the role of inhaled corticosteroids and ß2-agonists (2008) (3)
Respiratory effects of propafenone in asthmatic volunteers (1984) (3)
Management of COPD patients during COVID: difficulties and experiences (2021) (3)
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids (2017) (3)
Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome. (2012) (3)
Inhibiting or blocking LIGHT, a TNF superfamily member, for treating airway remodeling (2011) (3)
The need for a new fluoroquinolone. (2006) (3)
Serum erythropoietin concentration as a diagnostic tool for polycythemia vera. (2004) (3)
Erythropoietin pathophysiology and erythropoietin deficiency anemia. (2004) (3)
Mutational Landscape of the Transcriptome Offers a Rich Neoantigen Resource for Immunotherapy of Myeloproliferative Neoplasms (2018) (3)
Beyond Dual Bronchodilation – Triple Therapy, When and Why (2022) (3)
Cord blood-derived hematopoietic progenitor cells: in vitro response to hematopoietic growth factors and their recruitment into the S-phase of the cell cycle. (2000) (3)
Loss of Heterozygosity on Chromosome 9p24 Is the Most Frequent Chromosomal Aberration in Polycythemia Vera and Idiopathic Myelofibrosis. (2004) (3)
Air pollution and inflammatory airway disease: therapeutic options (2002) (3)
Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: implications for treatment of community-acquired lower respiratory tract infections. (1998) (3)
Comments on “Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations” by D’Amato et al. (2021) (3)
Introduction to a review series on myeloproliferative neoplasms. (2017) (3)
Toxic Epidermal Necrolysis Following Yersinia enterocolitica Infection (1993) (3)
The future of inhalation therapy in chronic obstructive pulmonary disease (2022) (3)
Perception Of Symptom Variability In Patients With Severe COPD: Impact On Morning Activities And Therapeutic Behaviour (2010) (3)
MYELOID NEOPLASIA JAK2 or CALR mutation status de ﬁ nes subtypes of essential thrombocythemia with substantially different clinical course and outcomes (2014) (3)
Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age (2013) (3)
Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudices. (2004) (3)
High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic (2012) (3)
Ring sideroblasts and myelodysplastic syndromes. (1983) (3)
Can EPO reduce blood transfusion requirements during induction therapy for high-risk neuroblastoma? (2004) (3)
A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD A double-blind, randomized, placebo-controlled trial (2017) (3)
Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network (2018) (3)
Chromosomal Aberration Network In Myeloproliferative Neoplasms (2010) (3)
Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs (2021) (3)
Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi (2014) (2)
Association Between Gene Expression Profiles and Commonly Mutated Genes In The Hematopoietic Stem Cells Of Patients With Myelodysplastic Syndromes (2013) (2)
Documentation of presence of a purinergic reactivity at tracheobronchial level in man (1985) (2)
Medical knowledge about COVID-19 is travelling at the speed of mistrust: why this is relevant to primary care (2022) (2)
Pyruvate kinase deficiency. (2005) (2)
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. (2018) (2)
[Correlation between pulmonary pharmacokinetics and pharmacodynamics support the hypothesis of the usefulness of ceftazidime at a single 1g daily dose in the treatment of bacterial exacerbation of chronic obstructive bronchopneumonia with moderate functional damage]. (1998) (2)
A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) (2011) (2)
Loss of Heterozygosity of Chromosome 1p34 and High Mutant Allele Burden in Patients with Post-Essential Thrombocythemia Myelofibrosis Carrying Somatic Mutations of MPL (2008) (2)
Predictive Value of Mutation Analysis in the Diagnostic Approach to Patients with Unexplained Cytopenia (2016) (2)
Salmeterol/Fluticasone Propionate A Review of its Use in the Treatment of Chronic Obstructive Pulmonary Disease (2007) (2)
Efficacy of respiratory tele-rehabilitation in COPD patients: Systematic review and meta-analysis. (2022) (2)
Tiotropium could provide benefits in the early stage of COPD, but further studies are needed (2018) (2)
Role of Macrolides as Immunomodular Agents (2006) (2)
Emerging anti-inflammatory strategies for chronic obstructive pulmonary disease (2012) (2)
The Future of Bronchodilators in COPD and Asthma. (2021) (2)
P136 Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need (2007) (2)
Somatic Mutations Are Frequently Detected in Chronic Myeloid Leukemia in Chronic Phase and Do Not Affect Response to Tyrosine-Kinase Inhibitors (2016) (2)
Ida Bianco Silvestroni. From red cell osmotic fragility to molecular biology of globin genes. A long, productive life with thalassemia. (1996) (2)
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma (2022) (2)
Developing a Classification of Hematologic Neoplasms in the Era of Precision Medicine. (2022) (2)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (2)
Systemic and ocular effects of alpha 2-adrenergic stimulating and beta 2-blocking agents. (1984) (2)
Lymphoproliferative Disorder of Large Granular Lymphocytes: Reversal of Lymphocyte Proliferation, Anemia and Neutropenia with Chlorambucil (1987) (2)
PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT (2019) (2)
Faculty Opinions recommendation of Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. (2019) (2)
Serum C-Terminal Telopeptide Maintains Its Correlation with Bone Disease in Myeloma Patients Even Under Treatment with Bisphosphonates (2012) (2)
Interaction between RPL554 and glycopyrronium bromide in small human airways (2014) (2)
Interaction between tiotropium bromide and olodaterol in small human airways (2017) (2)
C URRENT OPINION Comorbidities of asthma: current knowledge and future research needs (2013) (2)
Emerging antibacterial and antiviral drugs for treating respiratory tract infections (2018) (2)
Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis (2022) (2)
50 The identification of novel somatic mutations in MDS by whole exome sequencing (2011) (2)
Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review (2022) (2)
Therapeutic Strategies in COPD (2005) (2)
Lymphoplasmacytic Lymphoma Not Associated with an IgM Monoclonal Paraprotein Has Distinctive Clinical and Biological Features and a Similar Outcome As Compared with Waldenstrom's Macroglobulinemia: Multicentric Study of the Rete Ematologica Lombarda (2017) (2)
Experimental study with D-ozolinone and L-ozolinone metabolites of etozoline (1987) (2)
Molecular basis of myelodysplastic syndromes. (2012) (2)
Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis. (1994) (2)
A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group (2014) (2)
The natural history of hemochromatosis type 2. (2001) (2)
Abstract 5491: Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience (2015) (2)
Mutation Analysis of TET2 Reveals the Clonal Nature of Refractory Anemia with Ring Sideroblasts (2010) (2)
INCB018424, a Selective Inhibitor of JAK1 and JAK2, Downregulates the Expression of Leukocyte Alkaline Phosphatase (LAP) On Circulating Granulocytes in Patients with Polycythemia Vera and Essential Thrombocythemia. (2009) (2)
Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease (2016) (2)
Interferon-alpha protects Philadelphia-negative progenitors from exhaustion in chronic myeloid leukemia patients with cytogenetic response. (2001) (2)
Iron in hematology: an historical perspective. (2008) (2)
Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study (2015) (2)
Acute respiratory failure during pregnancy (2006) (2)
Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization (2017) (2)
IRON LOADING IN β-THALASSÆMIA (1980) (2)
Targeted Next Generation Sequencing Identifies Novel Genetic Mutations in Patients with Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma or IgM-Monoclonal Gammopathies of Undetermined Significance (2016) (2)
Drugs for the Treatment of Respiratory Diseases: Current and future management of pneumonia (2003) (2)
Molecular and clinical studies in hemochromatosis type 2 and 3 (2000) (2)
Anticholinergic agents. (1998) (2)
Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Who Classification-Based Prognostic Scoring System (WPSS) (2011) (2)
Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score (2022) (2)
The effects of adding formoterol (F) and tiotropium (T) on exercise performance and breathlessness in patients with COPD (2005) (2)
9 Refractory anemia with ringed sideroblasts (2007) (2)
Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits (2020) (2)
Comparative studies of dual bronchodilation in COPD. (2021) (2)
Editorial overview: Respiratory: Pulmonary pharmacology - It is time for a breath of fresh air. (2018) (2)
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm (2012) (2)
Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review. (2021) (2)
Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates (2014) (2)
Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients (2014) (2)
Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Revised International Prognostic Scoring System (IPSS-R) (2014) (2)
Flomoxef, a new oxacephem antibiotic, does not cause hemostatic defects. (1993) (2)
Haematopoietic growth factors in the treatment of myelodysplastic syndromes. (1999) (2)
The Effects of Mitochondrial Ferritin Expression in Normal and Sideroblastic Erythropoiesis. (2009) (2)
IDENTIFICATION OF ABERRANTLY SPLICED GENES AND DEREGULATED PATHWAYS/GENE ONTOLOGY THEMES IN MYELODYSPLASTIC SYNDROME PATIENTS WITH SPLICING FACTOR GENE MUTATIONS (2017) (2)
Unmet Needs and the Future of Asthma-Chronic Pulmonary Obstructive Disease Overlap. (2022) (2)
Effects of teicoplanin on human platelet aggregation in vitro and ex vivo. (1992) (2)
Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists (2020) (2)
SRSF2 Mutations Identify a Distinct Subtype of Myeloid Neoplasm Across Myelodysplastic Syndromes and Acute Myeloid Leukemia (2016) (2)
Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis (2012) (2)
Evaluation of the effects of pefloxacin on platelet aggregation in vitro and ex vivo in patients suffering from chronic bronchitis. (1995) (2)
Molecular control of iron metabolism in man (2004) (2)
Practice guidelines for the therapy of primary myelodysplastic syndromes: a word of caution about their translation into clinical practice. (2002) (1)
Should the Choice of a Long-Acting Bronchodilator in the Long-Term Therapy of Chronic Obstructive Pulmonary Disease Depend Entirely on the Onset of Action? (2006) (1)
Genuair® Is a Good Inhaler but an Indirect Comparison with Other Dry Powder Inhalers Is Inadequate (2009) (1)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (1)
Therapeutic implications of treatment with cefonicid on airway reactivity during bacterial lower respiratory tract infections (1989) (1)
Effect of exendin-4 on lung function of diabetic patients: a preliminary report (2017) (1)
Clues to the Pathogenesis of Waldenström Macroglobulinemia and Other Monoclonal IgM Disorders Provided by the Analysis of Immunoglobulin Heavy Chain Gene Rearrangement and Clustering of B-Cell Receptors, (2011) (1)
Prediction of Overall Survival in 520 Patients with Primary Myelofibrosis: Outcome Update of the Dynamic International Prognostic Scoring System (DIPSS) Patient Cohort (2012) (1)
Iron loading in beta-thalassaemia. (1980) (1)
Introduction to a review series on transfusion medicine. (2019) (1)
Clinical pharmacokinetics of teicoplanin and aminophylline during cotreatment with both medicaments. (1992) (1)
JAK2 (V617F)-Positive Essential Thrombocythemia and Polycythemia Vera Are Different Expressions Of a Genotypic/Phenotypic Continuum (2013) (1)
Newer Cephalosporins are Only Marginal Advancements Over Existing Compounds (2002) (1)
Effects of cefonicid on platelet aggregation. (1991) (1)
Microcytic anemia in rheumatoid arthritis. Relationship with activity and duration of the disease and iron status. (1986) (1)
High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents (2013) (1)
[Infections of the lower respiratory tract in general practice]. (1987) (1)
Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination (2020) (1)
Blood Eosinophils in Chronic Obstructive Pulmonary Disease: Is There Enough Evidence? (2021) (1)
Clonal Origin of Circulating Endothelial Progenitor Cells in Patients with Myelofibrosis with Myeloid Metaplasia. (2004) (1)
Mucolytic and Antioxidant Properties of Carbocysteine as a Strategy in COVID-19 Therapy (2022) (1)
Adult Cardiac Conditions (2014) (1)
Rebuttal From Drs Cazzola and Matera. (2018) (1)
Long-acting beta(2) agonists in asthma and allergic rhinitis. (2008) (1)
Evidence of muscarinic M1 receptors on human airways (1988) (1)
LABA/LAMA combination, exercise and lung hyperinflation in COPD: a meta-analysis (2017) (1)
The use of peripheral-blood hematopoietic progenitors mobilized with standard-dose chemotherapy plus granulocyte-colony-stimulating factor to support multicyclic dose-intensive chemotherapy for advanced breast-cancer. (1995) (1)
Role of 5-HT2 receptors on adenosine-induced contraction of guinea-pig isolated trachea (1992) (1)
842-6 Anemia is associated with reduced health status measures in patients with heart failure: Results from the STAMINA: HFP (study of anemia in a heart failure population) registry (2016) (1)
Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients (2020) (1)
VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials (2016) (1)
Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells (2010) (1)
Therapeutic strategies in acute exacerbations in COPD (2009) (1)
Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Commentary (2006) (1)
Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients (2014) (1)
ERRATUM: Myelodysplastic syndromes: Recent advances (Haematologica (2001) 86 (1124-57)) (2001) (1)
Role of 5-HT2 receptor subtypes in mediating adenosine-induced airway contraction. (1992) (1)
Fusion Gene Detection Using Whole Transcriptome Analysis in Patients with Chronic Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia (2015) (1)
How to prevent relapse after acute exacerbation of asthma? (2007) (1)
Sex differences in adult asthma and COPD therapy: a systematic review (2022) (1)
Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects (2014) (1)
Introduction to a How I Treat Series on Acquired Hemolytic Anemia. (2021) (1)
Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple therapy in COPD (2019) (1)
Use of recombinant human erythropoietin in anemia of malignancy. (1998) (1)
systemic-onset juvenile chronic arthritis erythropoietin production in the anemia associated with Defective iron supply for erythropoiesis and adequate endogenous (2009) (1)
Asthma and comorbidities: recent advances. (2022) (1)
Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today? (2022) (1)
Ensifentrine. Dual phosphodiesterase PDE3/4 inhibitor, Treatment of COPD, Treatment of cystic fibrosis (2019) (1)
Erythropoietin Level Red Blood Cell Precursor Mass as an Independent Determinant of Serum (2009) (1)
675 – EXPERIMENTAL ANALYSIS OF SOME INTERFERENCES BETWEEN PGF2α AND MORPHINE (1977) (1)
Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study. (2012) (1)
Introduction to a Review Series on Inherited Anemias. (2020) (1)
NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS BY GENE EXPRESSION PROFILING (2009) (1)
Syndromes Revised International Prognostic Scoring System for Myelodysplastic (2012) (1)
MYELOPROLIFERATIVE NEOPLASMS Diagnosis , risk strati fi cation , and response evaluation in classical myeloproliferative neoplasms (2017) (1)
Analysis of exhaled air for a rapid, sensible and specific diagnosis of COPD (2015) (1)
P147 Management of haematological adverse events in MDS patients treated with lenalidomide (2007) (1)
Myelodysplastic Syndromes. Reply. (2020) (1)
The trend of pulmonary function tests over time in COPD patients with different levels of blood eosinophils (2016) (1)
Bronchodilator Response as a Possible Predictor of Lung Function Improvement After Pulmonary Rehabilitation in Post-COVID-19 Patients (2021) (1)
Gender differences in COPD management in a Sicilian general practice setting: a cohort study evaluating the impact of educational interventions (2020) (1)
Differential Expression of Genes Related to JAK-STAT Pathway Activation or Megakaryocyte Differentiation/Maturation in CD34+ Cells from Patients with Refractory Anemia with Ringed Sideroblasts and Thrombocytosis (RARS-T). (2007) (1)
The 5T approach in asthma: Triple Therapy Targeting Treatable Traits. (2022) (1)
Faculty Opinions recommendation of Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. (2019) (1)
IDENTIFICATION OF ABERRANT SPLICING EVENTS IN MYELODYSPLASTIC SYNDROME PATIENTS WITH SPLICING FACTOR GENE MUTATIONS (2017) (1)
Introduction to a review series on germline predisposition to hematologic malignancy: Time to consider germline testing. (2023) (1)
Teicoplanin with other drugs: possible pharmacological interactions. (1993) (1)
A Review of its Efficacy in Chronic Obstructive Pulmonary Disease (2001) (1)
Evaluation of Virus-Specific T Cell Responses in Patients Affected with Myeloproliferative Neoplasms Treated with Ruxolitinib (2019) (1)
Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms (2017) (1)
Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes (2015) (1)
Muscarinic M-1 receptors mediate the bronchial hyperresponsiveness during methacholine inhalation. (1989) (1)
Long-acting muscarinic antagonists and small airways: which link? (2020) (1)
Lung blood flow must be considered when prescribing a long-acting β2-agonist/inhaled corticosteroid combination. (2012) (1)
New blood in Haematologica (2011) (1)
Molecular aspects of asthma. (2022) (1)
with chronic myelomonocytic leukemia Development and validation of a prognostic scoring system for patients (2013) (1)
Mechanisms leading to the bronchorelaxant synergy of ICS/LABA/LAMA combination (2019) (1)
Abnormal Regulation of Intracellular Calcium in Human Megakaryocytes Contributes to the Pathophysiology of Calr-Mutant Myeloproliferative Neoplasms (2018) (1)
Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients (2010) (1)
P-41 Aberrant mitochondrial iron distribution and maturation arrest characterizes early erythroid precursors in low-risk myelodysplastic syndromes (2005) (1)
Acute e V ect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease (1999) (1)
XVI meeting of the European Association for Haematopathology 2012 Abstracts (2012) (1)
COPD Identification By The Analysis Of Breath With An Electronic Nose (2011) (1)
Once‐weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production (2004) (1)
Editorial. A new respiratory journal. (2007) (1)
Ascorbic acid status in thalassemia major. (1984) (1)
The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset (2022) (1)
Efficacy of erdosteine, carbocysteine, and N-acetylcysteine in COPD: a comparative analysis (2019) (1)
Role of iron and proteins of iron metabolism in cell growth. Potential for manipulations of cellular iron metabolism in modulating cell proliferation. (1991) (1)
Granulocyte JAK2 (V617F) Mutation Status in Myeloid Neoplasms with Ringed Sideroblasts. (2006) (1)
Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group (2016) (1)
ACUTE EXACERBATIONS IN COPD (2009) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms. Blood First Edition Paper (2013) (1)
Practical recommendations on the management of non-haematological adverse events in MDS patients treated with lenalidomide (2007) (1)
Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects (2013) (1)
Clinical pharmacokinetics of teicoplanin and aminophylline (1992) (1)
Recombinant human erythropoietin to assist autologous blood donation by patients with anemia. (1997) (1)
C023 Expression profiling of CD34+ cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes (2007) (1)
Research on heterocyclic compounds. XV. Substitution influence on the pharmacological activity in a series of imidazo[1,2-a]pyridines. (1983) (1)
Whole Exome Sequencing Reveals Clonal Evolution of Myeloproliferative Neoplasms to Acute Myeloid Leukemia (2015) (1)
The Use of Triple Therapy in Chronic Obstructive Pulmonary Disease and Outcomes of the IMPACT Trial (2018) (1)
ERYTHROPOIESIS AND IRON KINETICS (1978) (1)
Rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by sequential use of nilotinib and imatinib: A GIMEMA protocol LAL 1408. (2013) (1)
Increased whole body hematocrit: Venous hematocrit ratio in diabetes mellitus, evidence of microcirculatory hemoconcentration (1984) (1)
This information is current as Macrophages Human NK Cells , Monocytes , and M 2 Imatinib and Nilotinib Off-Target Effects on (2017) (1)
Faculty Opinions recommendation of Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. (2019) (1)
Meningeal Leukemia following Lymphoid Blast Crisis in Chronic Myeloid Leukemia: Therapeutic Implications (1982) (1)
Advances in the Pharmacological Management of Pediatric Acute Respiratory Distress Syndrome (2021) (1)
A Rule-Based Expert System for Automatic Implementation of Somatic Variant Clinical Interpretation Guidelines (2019) (1)
Acute Effects of Urapidil on Airway Response in Hypertensive Patients with Chronic Obstructive Pulmonary Disease (2012) (1)
Driver Somatic Mutations and Transplantation Decision Making in Patients with Myelodysplastic Syndrome (2016) (1)
N-Acetylcysteine protects human bronchi via inhibiting neurokinin A (2017) (1)
IND/GLY/MF: synergism in medium and small human hyperresponsive airways (2020) (1)
Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis. (2007) (1)
Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile (2022) (1)
C‐FMS EXPRESSION IN B‐CELLS AND RESPONSE TO M‐CSF (1993) (1)
Abnormal splenic uptake of red cells in long-lasting iron deficiency anemia due to self-induced bleeding (factitious anemia) (1978) (1)
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin (2014) (1)
Safety profile of triple ICS/LABA/LAMA FDC in the treatment of asthma: a meta-analysis (2022) (0)
Chronic obstructive pulmonary disease b2-Agonists Antimuscarinic agents Methylxanthines Choice of bronchodilators Emerging bronchodilators (2014) (0)
Introduction to a Review Series on Normal and Pathologic Erythropoiesis. (2022) (0)
Efficacy and safety of ICS/LABA/LAMA FDCs in COPD: a network meta-analysis (2022) (0)
Phenotypes and Specific Mutations in the Iron-Responsive Element of Hereditary Hyperferritinemia-Cataract Syndrome: Relationship Between (2013) (0)
Common Variation at 6q25.3 (TULP4) Influences Risk for Arterial Thrombosis in Myeloproliferative Neoplasms (2015) (0)
Nervous system involvement in acute myeloid leukaemia. (1978) (0)
Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis. (2012) (0)
ES4 The Possibility of New LABA and LAMA combination therapy in COPD (2012) (0)
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (2018) (0)
Treatment of COPD: no longer nihilism, but there is still an urgent need for new therapies. (2012) (0)
Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q) (2008) (0)
Congenital erythropoietin-dependent erythrocytosis responsive to theophylline treatment. (1998) (0)
Use of recombinant human erythropoietin in the treatment of myelodysplastic syndromes (2002) (0)
Preface [Hot Topic: Novel and Alternative Non-Steroidal Treatments for Asthmatic Inflammation (Guest Editor: Mario Cazzola)] (2004) (0)
Incidence and burden of major comorbidities among individuals with COPD: a comprehensive analysis using data from primary care (2009) (0)
Very primitive haemopoietic cells are present in Philadelphia negative cytapheresis collected during early recovery following chemotherapy-induced aplasia in patient with chronic myeloid leukaemia and are able to restore polyclonal haematopoiesis when autografted after chemotherapy and TBI (1994) (0)
Current and emerging treatment modalities for bacterial rhinosinusitis in adults: a comprehensive review (2022) (0)
24 COMPREHENSIVE ANALYSIS OF ALTERNATIVE RNA SPLICING IN MYELODYSPLASTIC SYNDROMES (2015) (0)
Indacaterol/Glycopyrronium in Clinical Practice: The Italian Experience (2018) (0)
Mutational Status of TET2, JAK2, and MPL in Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis. (2009) (0)
Effects of lomefloxacin and sparfloxacin on human platelet aggregation. (1995) (0)
Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis (2013) (0)
There is still no established and accepted definition of COPD. (2023) (0)
Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509 (2011) (0)
COMPREHENSIVE ANALYSIS OF MUTATION STATUS, GENE EXPRESSION PROFILES, BLOOD AND BONE MARROW COUNTS AND OUTCOME IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (2014) (0)
Chronic obstructive pulmonary disease: treatment (Part Two) (2006) (0)
Anti-inflammatory profile of N-acetylcysteine in human bronchi stimulated with lipopolysaccharide (2016) (0)
Essential Thrombocythemia. (2020) (0)
Preliminary data on androgen treatment of haemopoietic dysplasias. (1980) (0)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (0)
[Epidemiological studies of chronic bronchitis in the auxiliary personnel of the A. Cadarelli Hospital. Preliminary results]. (1975) (0)
Confocal Microscopy Is Useful for Detection of Bortezomib Related Neuropathy (BOR-PN) in Multiple Myeloma (MM) Patients (PTS) (2014) (0)
[Ventilatory and cardiovascular effects of a new beta stimulating agent, terbutaline, administered subcutaneously in patients with bronchial obstruction]. (1977) (0)
N95 Respirators or Surgical Masks to Protect Healthcare Workers against Respiratory Infections: Are We There Yet? (2013) (0)
Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides. (2000) (0)
Pharmacological characterization of the protective effect of mepolizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma (2019) (0)
151 A patient-oriented approach to the use of erythropoietin in myelodysplastic syndromes (1997) (0)
Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS (2018) (0)
Faculty Opinions recommendation of Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. (2019) (0)
Treatment of difficult Gram-positive infections (2004) (0)
Synergistic interaction between beclomethasone diproprionate and formoterol fumarate in an ex vivo model of bronchial asthma (2018) (0)
Physiologic and biological markers to assess the progression of chronic obstructive pulmonary disease [Quali parametri funzionali e biologici per la valutazione della progressione della broncopneumopatia cronica ostruttiva] (2008) (0)
Mucolytics/antioxidants: When Are They Useful? (2023) (0)
Cardiovascular Complications of Respiratory Disorders (2020) (0)
The Challenges of Precision Medicine in COPD (2017) (0)
AFTER 77 YEARS, HAEMATOLOGICA IS STILL GROWING STEADILY (1997) (0)
24 Outcomes and endpoints in COPD clinical trials (2007) (0)
COPD_A_345263 165..180 (2022) (0)
Chronic myeloproliferative diseases: Polycythemia, thrombocythemia, myelofibrosis - Preface (2006) (0)
Introduction to a How I Treat Series on Anemia. (2020) (0)
A Novel Approach to a Retrospective Longitudinal Analysis of Dose Change or Discontinuation of Imatinib Therapy in Chronic Phase–Chronic Myeloid Leukemia (2014) (0)
Indacaterol/mometasone furoate combination: synergism in human hyperresponsive airway smooth muscle (2020) (0)
High resolution cytogenetic mapping and whole exome sequencingreveal a complx pattern of chromosome 6p aberrations inpatients with myeloid malignancies. (2015) (0)
syndromes characterize early erythroid precursors in low-risk myelodysplastic Aberrant mitochondrial iron distribution and maturation arrest (2013) (0)
Erythrokinetics and mechanisms of anaemia in hereditary elliptocytosis and hereditary ovalocytosis. (1982) (0)
IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers (2015) (0)
The Identification of a Mathematical Model for the Investigation of the Differences Between Monoferric and Diferric Transferrin in Man (1985) (0)
Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia (2014) (0)
Comparative evaluation on the synergism of roflumilast (RFL) and glycopyrronium (Gly) vs ciclesonide (CLS) and Gly on lung volumes and exercise tolerance in severe COPD (2015) (0)
Bidimensional comparative analysis of LABA/LAMA FDCs in COPD (2019) (0)
Brensocatib. Dipeptidyl peptidase 1 (DPP1) inhibitor, Treatment of non-cystic fibrosis bronchiectasis (2021) (0)
myelofibrosis in primary MPL , or CALR , JAK2 Clinical effect of driver mutations of (2014) (0)
hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) recombinant interferon-alpha on chronic myelogenous leukemia Synergistic antiproliferative effect of recombinant interferon-gamma with (2013) (0)
adults : recommendations from the European LeukemiaNet Diagnosis and treatment of primary myelodysplastic syndromes in (2013) (0)
COVID-19-vaccination in patients receiving allergen immunotherapy (AIT) or biologics - EAACI recommendations (2021) (0)
Postgraduate Course ERS Glasgow 2004: Antibiotics (2004) (0)
Impact of age-related comorbidities on the risk of COPD exacerbations in subjects with severe airflow limitation: A pan-European study (2013) (0)
Systemic pharmacotherapy (2019) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
[Activity against clotting and platelet aggregation of the anticoagulant fraction of venom from Agkistrodon rhodostoma]. (1975) (0)
JAK2 (V617F) Mutation and Cerebral Venous Thrombosis (2011) (0)
[Morphological and cytochemical studies of megakaryocytes in 25 patients with haemopoietic dysplasias (author's transl)]. (1980) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
Mineral water and aspecific bronchial reactivity (1992) (0)
P-14 Demographic and disease-related prognostic factors in myelodysplastic syndromes classified according to who criteria (2005) (0)
Clinical characteristics, treatment patterns and adherence in patients with asthma on multiple inhaler triple therapy: a review of findings (2022) (0)
[Bronchial reactivity tests]. (1989) (0)
As needed therapies in mild to severe asthma: a systematic review and network meta-analysis (2020) (0)
Improved method for liquid scintillation counting of $sup 59$Fe in ferrokinetic studies (1974) (0)
[Myelodysplastic syndromes: mechanisms of transformation and neoplastic progression and their clinical implications]. (1991) (0)
Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved. (2018) (0)
Beclomethasone, formoterol and glycopyrronium: effect on an ex vivo model of COPD exacerbation (2020) (0)
Preclinical Advances in the Pathogenesis and Therapy of Myeloproliferative Neoplasms TET 2 (2012) (0)
Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials (2015) (0)
Evidence of Polyclonal Hematopoiesis in a Large Proportion of Patients with Low-Risk Myelodysplastic Syndrome. (2004) (0)
The role of pharmacological treatment in the clinical deterioration of COPD: Can it be slowed down? (2022) (0)
An International Multicenter Project on Secondary Myelofibrosis (2016) (0)
Faculty Opinions recommendation of Bronchodilators, receptors and cross-talk: Together is better? (2019) (0)
Related articles (2014) (0)
P.10.16 INTESTINAL PERMEABILITY IS INCREASED IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH AND WITHOUT GASTROINTESTINAL SYMPTOMS (2018) (0)
Impact of glucagon-like peptide 1 receptor agonists on lung function of diabetic patients: a 52 weeks clinical trial (2018) (0)
Germline RBBP6 mutations in familial myeloproliferative neoplasm (2016) (0)
comments) hematologic disorders. Results of a phase I/II clinical trial (see Subcutaneous erythropoietin for treatment of refractory anemia in (2009) (0)
UNCORRECTED PROOF Primary care of the patient with chronic obstructive pulmonary disease (2008) (0)
Themed Section: Analytical Receptor Pharmacology in Drug Discovery (2010) (0)
Influence Of Sensory Nerves And Neutral Endopeptidase On Human Isolated Bronchial Contraction Mediated By Adenosine A1 Receptor Activation (2011) (0)
Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone (2016) (0)
Relationship between JAK2 V617F Mutation Status and Constitutive Mobilization of CD34-Positive Cells into Peripheral Blood in Patients with Chronic Myeloproliferative Disorder. (2005) (0)
Clinical Significance of Tumor-Associated Macrophages in Early-Stage Hodgkin's Lymphoma. (2012) (0)
The effect of ascorbic acid supplementation on serum ferritin concentration in normal subjects. (1985) (0)
Effects of MAPK inhibitors on H2O2-induced IL-8 production and cell death in primary cultures of human bronchial epithelial cells (2004) (0)
A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD (2016) (0)
COPDCoRi, an algorithm for predicting the risk of coronaropathy in COPD patients (2014) (0)
myeloid and lymphoid neoplasms in SF3B1 Biologic and clinical significance of somatic mutations of (2013) (0)
matched historical controls JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to Long-term outcomes of 107 patients with myelofibrosis receiving (2013) (0)
Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report (2017) (0)
Faculty Opinions recommendation of Glucocorticosteroids. (2019) (0)
[Adequate surrogate parameters in COPD studies]. (2007) (0)
COPD : the patient perspective Paul (2016) (0)
Faculty Opinions recommendation of A new approach to the classification and management of airways diseases: identification of treatable traits. (2019) (0)
Fotemustine (MUFORAN) in Combination with Once Weekly Bortezomib and Dexamethasone (B-MuD): Good Clinical Activity and Favourable Toxicity Profile for Treatment of Relapsed Multiple Myeloma Patients. (2012) (0)
Faculty Opinions recommendation of Inhaled corticosteroid containing combinations and mortality in COPD. (2019) (0)
RNA missplicing and ring sideroblasts in MDS. (2022) (0)
Effect of N-acetylcysteine on the activity of antibiotics against relevant respiratory pathogens (2016) (0)
Adequate surrogate parameters in COPD studies [Surrogatparameter bei COPD] (2007) (0)
Pharmacological characterization of the anti-oxidant activity of N-acetylcysteine in anex vivomodel of COPD exacerbation (2016) (0)
The plasma59Fe clearance curve in man (1980) (0)
Long-acting bronchodilators and synergistic interaction: a challenge across the currently available LABA/LAMA combinations (2018) (0)
Prevalence and clinical relevance of comorbidities in IPF (2018) (0)
Tozorakimab. Anti-IL-33 monoclonal antibody, Treatment of COPD and asthma, Treatment of atopic dermatitis, Treatment of diabetic kidney disease (2023) (0)
Outcome Measures and Prognostic Markers for COPD (2011) (0)
Prospective Clinical and Epidemiological Evaluation of rHuEPO in the Routine Care of a Network of Hematological Centers. (2004) (0)
Asthma and bacterial infection: role of antibiotic therapy (1992) (0)
Proliferation kinetics of bone marrow cells in congenital dyserythropoietic anemia type II (1985) (0)
[Evaluation of hemodynamic, ventilatory and blood-gas effects of terbutaline administered intravenously in various doses in patients with spastic bronchial obstruction]. (1977) (0)
Fotemustine IN COMBINATION with BORTEZOMIB and DEXAMETHASONE: Encouraging PRELIMINARY RESULTS FROM A PHASE II STUDY On Relapsed REFRACTORY MYELOMA PATIENTS (2010) (0)
The Possibility of New combination therapy in COPD (2014) (0)
Incidence and Clinical Significance of SF3B1 Somatic Mutation in Chronic Lymphocytic Leukemia. (2012) (0)
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group (2014) (0)
Optimizing bronchodilation in chronic obstructive pulmonary disease: is it possible? (2010) (0)
Bone Marrow Aspirate Can Be Avoided in Low-Risk MGUS Patients (2012) (0)
thrombocythemia carrying the JAK2 (617V>F) mutation Increased risk of pregnancy complications in patients with essential (2013) (0)
Myeloproliferative Neoplasms Research and Treatment ) formyelofibrosis : a study by the IWG-MRT ( International Working Group A dynamic prognostic model to predict survival in primary (2010) (0)
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis (2020) (0)
Biologic therapies for chronic obstructive pulmonary disease (2022) (0)
Ciril Rozman. El reto asumido (The challenge accepted) (2009) (0)
treated with ruxolitinib in the COMFORT-II study Impact of mutational status on outcomes in myelofibrosis patients (2014) (0)
Somatic Mutations of ASXL1, RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia (2014) (0)
C019 Genome-wide analysis of copy number change and loss of heterozygosity in myelodysplastic syndrome with del (5q) using high-density SNP arrays (2007) (0)
Risk stratifying MDS in the time of precision medicine. (2022) (0)
Bronchial reactivity and menstrual cycle (1992) (0)
Clonal Analysis of SF3B1, JAK2 and MPL in Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis (2012) (0)
Pharmacology of the small airways [Farmacologia delle piccole vie aeree] (2009) (0)
Effect of recombinant gamma interferon on the proliferative activity of cultured leukemic cells. (1988) (0)
Faculty Opinions recommendation of Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. (2019) (0)
Bronchiectasis and COVID-19 infection: a two-way street (2022) (0)
Beclomethasone, formoterol and glycopyrronium: synergism of triple therapy on human airways (2019) (0)
Mechanisms leading to the bronchoprotective effects of N-Acetylcysteine in human bronchi stimulated by lipopolysaccharide (2018) (0)
Editorial overview: Respiratory: Pulmonary pharmacology–The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives (2021) (0)
20 Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (2009) (0)
[BR 750 (2,6-dichloro-benzilidene amino guanidine acetate), skeletal musculature and neuromuscular transmission]. (1974) (0)
Pharmacological Control of Airways in Health and Diseases. Capri, Italy, October 1998. Preface. (1998) (0)
Deferoxamine in thalassemia major. (1995) (0)
Combined DNA and Transcriptome Sequencing Reveals Discrete Subtypes of Myelodysplasia (2016) (0)
Pharmacotherapy of LAMA/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview (2022) (0)
Moving to a Personalized Approach in Respiratory Medicine. From Academic Research to Regulatory Intervention (2021) (0)
Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis (2018) (0)
Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration (2016) (0)
High rate of complete hematological response in elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of nilotinib and imatinib: a GIMEMA clinical trial LAL 1408. (2015) (0)
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia (2018) (0)
Pharmacological Therapy: Bronchodilators (2011) (0)
Faculty Opinions recommendation of Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. (2019) (0)
Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes (2008) (0)
Pincered red cells and hereditary spherocytosis. (1981) (0)
Faculty Opinions recommendation of Chronic Use of Theophylline and Mortality in Chronic Obstructive Pulmonary Disease: A Meta-analysis. (2019) (0)
Infection perturbs Bach2- and Bach1-dependent erythroid lineage ‘choice’ to cause anemia (2018) (0)
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project (2018) (0)
Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate (2016) (0)
myeloproliferative disorders Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative (2013) (0)
Rearrangements of Tyrosine Kinase (TK) Genes in Chronic Myeloproliferative Disorders (CMPD): A FISH Study (2016) (0)
P036 Diagnostic utility of flow cytometry in myelodysplastic syndromes lacking conventional diagnostic markers: a prospective validation study (2009) (0)
S06 Clinical relevance and treatment of transfusional iron overload in myelodysplastic syndromes (2007) (0)
[Pathogenetic mechanisms of chronic myeloid leukemia and the antiproliferative effects of alpha and gamma interferons]. (1990) (0)
Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated with t(8;9)(p22;p24) and PCM1-JAK2 Fusion Gene. (2012) (0)
HFE, iron homeostasis and genetic hemochromatosis. (2000) (0)
Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study (2019) (0)
[Evaluation of the accuracy of 59 Fe measurements in ferrokinetic studies using solid and liquid scintillation counting]. (1975) (0)
Pharmacological characterization of the protective effect of benralizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma (2019) (0)
hemochromatosis Spectrum of hemojuvelin gene mutations in 1q-linked juvenile (2013) (0)
Anemia associata ad endocrinopatie. (1992) (0)
myeloproliferative disorders and constitutive mobilization of CD34+ cells into peripheral blood in Relation between JAK2 (V617F) mutation status, granulocyte activation, (2013) (0)
Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients (2018) (0)
Acknowledgement to Referees (2013) (0)
Clinically important deterioration: a composite tool for managing patients with COPD. (2022) (0)
Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema (2016) (0)
Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms (2019) (0)
YI1 Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets (2009) (0)
Faculty Opinions recommendation of How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease? (2019) (0)
Characterization of Chromosome 6q Deletions in MYD88 Mutant and Wild-Type Waldenström's Macroglobulinemia (2017) (0)
Title Aberrant splicing and defective mRNA production induced bysomatic spliceosome mutations in myelodysplasia (2019) (0)
Perception Of Symptom Variability In Patients With Symptomatic COPD (2010) (0)
Cell cycle characteristics of CD34+ hematopoietic stem cells (HSC) after FEC chemotherapy + colony-stimulating factors (CSF's) (1994) (0)
An answer to Leonardo Fabbri (2012) (0)
editor: Germline RBBP6 mutations in familial myeloproliferative neoplasms (2016) (0)
[Experimental studies on the pharmacokinetics of lividomycin A]. (1975) (0)
CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles (2017) (0)
treating chronic obstructive pulmonary disease The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for (2010) (0)
Onset of action of aclidinium (ACL), glycopyrronium (GLY) and tiotropium (TIO): A comparison in COPD patients (2015) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
Asthma treatment must be always tailored to the individual patient. (2002) (0)
Myelodysplastic Syndromes Myelodysplastic syndromes : recent advances (2001) (0)
New long—acting β2—agonist inhalers (2012) (0)
PF669 RUXOLITINIB TREATMENT AND RISK OF B-CELL LYMPHOMAS IN MYELOPROLIFERATIVE NEOPLASMS (2019) (0)
CLINICAL AND MOLECULAR CHARACTERISTICS OF SRSF2-MUTATED NEOPLASMS (2019) (0)
exon 12 mutations JAK2 associated with Molecular and clinical features of the myeloproliferative neoplasm (2013) (0)
238 Cell kinetics of hematopoietic progenitors following chemotherapy (CT) plus colony-stimulating factors (CSF'S) in advanced breast cancer (1995) (0)
Chromosomal Aberrations in Therapy-Related Myelodysplastic Syndromes – Relations to Primary Disease, Therapy and Prognostic Significance (2017) (0)
Distinct genetic lesions drive leuekmogenesis in secondaryacute myeloid leukemia (2011) (0)
High-resolution genomic profiling of myelodysplasia (MDS) by microarray comparative genomic hybridization (CGH). (2006) (0)
Interaction between aclidinium bromide and formoterol fumarate; effects on human bronchial smooth muscle (2014) (0)
Waldenström's hyperglobulinemic purpura in HLA identical sisters. (1984) (0)
Bronchodilator Response as a Possible Predictor of Lung Function Improvement After Pulmonary Rehabilitation in Post-COVID-19 Patients. (2021) (0)
Bronchodilators in bronchiectasis: there is light but it is still too dim (2022) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
PF655 PROGNOSTIC RELEVANCE OF THE GENE EXPRESSION SIGNATURE IN PRIMARY AND SECONDARY MYELOFIBROSIS (2019) (0)
Reviews: Comparative effectiveness of drugs for chronic obstructive pulmonary disease. (2012) (0)
Global burden of COPD and limitations to current management strategies (2014) (0)
Antimicrobial susceptibility in isolated microorganisms in tracheal aspirates of intensive care patients (2018) (0)
The Revised International Prognostic Scoring System (IPSS-R) Predicts Posttransplantation Outcome Of Patients With Myelodysplastic Syndrome Receiving Allogeneic Stem Cell Transplantation: A Basis For Clinical Decision Making (2013) (0)
Faculty Opinions recommendation of Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. (2019) (0)
Qualitative aspects of exertional dyspnea in ILD patients before and after oxygen supplementation (2015) (0)
RESPONSIVENESS AND SENSITIVITY TO CHOLINERGIC AGONISTS AND ANTAGONISTS IN BOVINE ISOLATED BRONCHIAL MUSCLE (1992) (0)
Once- vs. twice-daily inhaled therapy in asthma: a network meta-analysis (2019) (0)
Faculty Opinions recommendation of Inhaled corticosteroids in COPD: the final verdict is…. (2019) (0)
MYELOID NEOPLASIA The genetic basis of myelodysplasia and its clinical relevance (2013) (0)
Cardiovascular disease in asthma patients: from mechanisms to therapeutic implications. (2023) (0)
[Absence of pharmacokinetic interference between flunisolide and salbutamol]. (1984) (0)
Corticosteroids and Delayed Conversion of SARS-CoV-2 RNA Nasopharyngeal Swabs in Hospitalized Patients With COVID 19 Pneumonia (2021) (0)
An Investigation Of The Role Of Histamine And Leukotrienes In Adenosine A1 Receptor Mediated Contraction Of Passively Sensitized Human Bronchial Preparations In Vitro (2011) (0)
Characterization of Chromosome 20q Deletions In Myeloproliferative Neoplasms Using Microarray Karyotyping and Next-Generation Sequencing (2010) (0)
Effects of 5-HT2 receptor blockade on ventilation during exercise in chronic airway obstruction patients (1987) (0)
Faculty Opinions recommendation of Inhaled corticosteroids in COPD: friend or foe? (2019) (0)
The state of the journal: 1998 achievements and future objectives. (1998) (0)
Molecular genetics in clinical decision making for patients with myelodysplastic syndromes or related disorders (2018) (0)
Effects Of Adenosine Receptor Agonist And Antagonists On Human Isolated Bronchi (2010) (0)
Long-acting beta2-agonists for chronic obstructive pulmonary disease: Serious adverse events (2008) (0)
International Consensus Classification for myeloid neoplasms at‐a‐glance (2022) (0)
Practical management of asthma, 2nd edition (1996) (0)
Effects of some antibiotics on human platelet aggregation (1992) (0)
Traumatic haemolysis with iron deficiency anaemia in a patient with mitral regurgitation. (1977) (0)
Chapter 27 – Bronchodilators: Beta2-Agonists and Anticholinergics (2008) (0)
72 Recruitment and identification of “normal” hematopoietic cells in MDS (1997) (0)
Ask the expert: New directions in asthma therapy (2007) (0)
Iconographies supplémentaires de l'article : Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients (2015) (0)
PGF2alpha and nictitating membrane: an experimental study in vivo and in vitro. (1975) (0)
Comprar Chronic Obstructive Pulmonary Disease: Outcomes and Biomarkers | Mario Cazzola | 9781420084603 | Informa Healthcare (2009) (0)
Penetration of cefonicid into human lung tissue and lymph nodes. (1990) (0)
The role of inhaled combination therapy with corticosteroids and long-acting β 2 -agonists in the management of COPD (2005) (0)
Whole Exome Sequencing Identifies Somatic Mutation Patterns Of Myeloid Cells In Patients With Myeloproliferative Neoplasms Treated With Allogeneic Bone Marrow Transplantation (2013) (0)
Clinical Phenotype and Genotype Correlations with Time to Progression into Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis (2017) (0)
Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts (2013) (0)
Long‐ And Ultra‐Long‐Acting β22‐Agonists (2012) (0)
Navafenterol. Dual M3 receptor antagonist/beta2-adrenoceptor agonist (MABA), Treatment of chronic obstructive pulmonary disease (2022) (0)
Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups (2015) (0)
Interaction between aclidinium bromide and formoterol fumarate in small human airways (2014) (0)
Erythropoiesis Is Highly Stimulated in CD34 + Cells in Low-Risk Myelodysplastic Syndromes (MDS) with an Improper Mitochondrial Function. (2004) (0)
normal humans Transferrin saturation, plasma iron turnover, and transferrin uptake in (2011) (0)
Corrigendum: Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells (vol 29, pg 1092, 2015) (2015) (0)
COPD_A_221852 2733..2744 (2019) (0)
[Pharmacodynamic aspects of corticosteroids for topical use with special regard to beclomethasone dipropionate]. (1975) (0)
Searching for synergistic interaction between aclidinium (ACL) and formoterol (FOR): From bench to bedside (2015) (0)
IL9 Comorbidities in asthma and COPD (2012) (0)
Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes (2023) (0)
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia (2014) (0)
Adding glycopyrronium to beclomethasone/formoterol combination: synergistic effect on human medium bronchi of COPD donors (2021) (0)
A translational link between Fe and Epo. (2013) (0)
Genome-Wide Analysis of Non-Coding Alterations in Pan-Myeloid Cancers Using Whole Genome Sequencing (2018) (0)
Publish or perish: prospects for European Hematological Journals. (1996) (0)
Gene Expression Profiling Defines a Set of New Molecular Markers for Sporadic and Familial Myeloproliferative Disorders. (2004) (0)
Analysis of Factors Predicting Response to Recombinant Human Erythropoietin in Nonrenal Anaemia (1992) (0)
The Role of Respiratory Drugs in Gastroesophageal Reflux (1999) (0)
Amides of benzonorbornen-2-endo-amine with local anesthetic and other activities. (1984) (0)
granulocyte-monocyte progenitors Effect of acidic and basic isoferritins on in vitro growth of human (2011) (0)
Monographs: Indacaterol for chronic obstructive pulmonary disease (COPD) (2010) (0)
Onset of action of formoterol/budesonide (F/B) Spiromax® compared with F/B Turbuhaler® in patients with COPD: A preliminary report (2016) (0)
General pharmacological considerations in antibiotic treatment of community-acquired pneumonia. (2008) (0)
Reviews of "Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants" (2021) (0)
The Plasma S 9 Fe Clearance Curve in Man * An Evaluation of Methods of Measurement and Analysis (0)
Italian cooperative study on idiopathic hypereosinophilic syndrome (HES): FIP1-L1/PDGFRA rearrangement can be effectively treated with imatinib (2003) (0)
The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis [Corrigendum] (2018) (0)
A GENOMEWIDE ASSOCIATION STUDY IDENTIFIES NOVEL LOCI THAT PREDISPOSE TO MYELOPROLIFERATIVE NEOPLASMS (2013) (0)
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS (2022) (0)
Clinical and Molecular Features Of Myeloid Neoplasms Carrying SRSF2 Mutation (2013) (0)
Sequential Evaluation of the Proportion of Granulocyte JAK2 (V617F) Mutant Alleles in Chronic Myeloproliferative Disorders. (2006) (0)
S135 NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS (2019) (0)
The transcriptional and alternative splicing landscape of myelodysplastic syndromes (2016) (0)
Experimentaland clinical study of ticarcillin + clavulanic acid on theophylline pharmacokinetics (1992) (0)
Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression (2014) (0)
Gene expression pro ﬁ le correlates with molecular and clinical features in patients with myelo ﬁ brosis (2021) (0)
Genetic Determinants Of Disease Phenotype In Myelodysplastic Syndromes (2013) (0)
GCLLSG patients treated with alemtuzumab : results from the CLL 2 H trial of the mutations in fludarabine-refractory CLL (2013) (0)
Retraction: High, but not low, molecular weight preparations of hyaluronic acid protect asthmatics against challenge-induced bronchoconstriction (2009) (0)
Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies (2022) (0)
Defining Phenotypes in COPD: An Aid to Personalized Healthcare (2014) (0)
Expression Profiling of CD34+ Cells in Patients with Myelodysplastic Syndromes: Involvement of Interferon-Stimulated Genes and Correlation to FAB Subtype and Karyotype. (2006) (0)
Effect of flomoxef on human platelet aggregation (2004) (0)
AUTHOR PROOF COPY Not for publication (2015) (0)
71 Pathogenetic and prognostic role of vascular endothelial growth factor in myelodysplastic syndromes (2011) (0)
In memoriam, Professor Bo Lundbäck (1948-2022), Respiratory Medicine Associate Editor. (2023) (0)
From the authors (2008) (0)
Antioxidants and Protease Inhibitors (2003) (0)
[Chronic granulocytopenia associated with exposure to isopropylphenazone, complicated by two episodes of acute agranulocytosis caused by aminopyrine (author's transl)]. (1978) (0)
A long-term (2 years) efficacy and safety study of doxofylline in the treatment of asthma (2019) (0)
Ensifentrine: A First-in-class Bifunctional Drug for the Treatment of Chronic Obstructive Pulmonary Disease (2022) (0)
Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis (2019) (0)
Omalizumab: Stepping Outside Our Comfort Zone to Broaden the Number of Those Who Can Benefit (2014) (0)
[In-vivo antibacterial activity of an aminoglucoside antibiotic: lividomycin A]. (1975) (0)
Updated GOLD COPD Recommendations (2017) (0)
The Impact of Driver Mutations of JAK2, Calr, or MPL in Patients with Myelofibrosis Undergoing Hemopoietic Stem Cell Transplantation (2015) (0)
Genetic Determinants of Disease Phenotype and Clinical Outcome in Myelodysplastic Syndromes with Ring Sideroblasts (2014) (0)
Introducing COPD Research and Practice (2015) (0)
Erratum: Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders (British Journal of Haematology (2004) 126 (650-656)) (2005) (0)
Erratum to Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo, [Cancer Cell, 25, 2014, 794-808] (2014) (0)
Introduction to a review series on classical myeloproliferative neoplasms. (2023) (0)
Liquid scintillation counting for 59Fe and 51Cr in erythrokinetic studies (1980) (0)
[In-vitro antibacterial activity of an aminoglucoside antibiotic: lividomycin A]. (1975) (0)
P-37 Flow cytometric analysis of cytosolic and mitochondrial ferritins in immature red blood cells from patients with myelodysplastic syndrome (2005) (0)
A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD (2022) (0)
LYMPHOID NEOPLASIA Prevalence and clinical signi ﬁ cance of the MYD88 (L265P) somatic mutation in Waldenstr¨om ’ s macroglobulinemia and related lymphoid neoplasms (2013) (0)
Relationship between JAK2 V617F Mutation Status, Granulocyte CD177 mRNA Expression and CD177 Soluble Protein Level in Patients with Polycythemia Vera. (2005) (0)
Safety of Long-Acting Beta-Agonists in Asthma ASTHMA THERAPY (0)
Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41 (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Mario Cazzola?

Mario Cazzola is affiliated with the following schools: